

Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction

Received: 5 January 2024

Accepted: 28 January 2026

Published online: 12 March 2026

 Check for updates

David Smyth¹, Liyong Zhang¹, Mohammad Al-Khalaf¹, Sabrina Robichaud¹, Richard Seymour¹, Michele Geoffrion¹, Richard Jung¹, Simon Parlow¹, Feng Du¹, Brian McNeill¹, Qiujiang Du¹, Caroline Beauregard¹, Xiaoling Zhao¹, Mireille Ouimet^{1,2}, Shawn T. Beug^{2,3}, Eric C. LaCasse³, Katey J. Rayner^{1,2}, Tak W. Mak⁴, Benjamin Hibbert^{1,5}, Robert G. Korneluk^{2,3} & Peter P. Liu^{1,5}✉

Ischemic heart disease, driven largely by myocardial infarction (MI), remains the leading cause of mortality and morbidity. Although early suppression of post-MI inflammation improves outcomes, current therapies have limited efficacy. Here we show that the cellular inhibitor of apoptosis 2 (cIAP2), a regulator of cell death, is upregulated after MI and promotes acute inflammation and cardiac injury. Global deletion of cIAP2, or its loss through bone marrow transfer, reduced inflammatory injury and cardiac dysfunction after MI, indicating that the cardioprotective effect of cIAP2 deficiency is primarily mediated by the hematopoietic compartment. Reduced cardiac inflammation was associated with decreased splenic myeloid cell numbers due to increased cell death and elevated expression of the death-inducing factors TRAIL and TRAIL-R2/DR5. Pharmacologic degradation of cIAP proteins after MI using Smac mimetics similarly reduced cardiac inflammation and protected against injury. Together, these findings identify cIAP2 as a key hematopoietic cell-expressed regulator of survival and inflammation and support its inhibition as a potential immunotherapeutic strategy for MI.

Although incidence rates of MI are stabilizing, and survival after acute MI has improved, MI continues to be a major cause of significant morbidity and progression toward heart failure^{1,2}. An effective early inflammatory response is required to promote clearance of dead cells from infarcted tissue and stimulate robust wound healing³, but limiting the intensity and duration of this response is beneficial in mitigating the development of chronic disease^{4,5}. Success of this strategy has been suggested by encouraging results from clinical trials evaluating chronic inhibition of key inflammatory cytokines such as interleukin-1 beta (IL-1 β)

and interleukin-6 (IL-6)^{6,7} or broader anti-inflammatory agents such as colchicine that interfere with inflammasome assembly⁸. However, these molecules have broad, multifaceted biological functions, and long-term inhibition of their activities can lead to adverse effects—namely, elevated risk of infection. Furthermore, high costs, route of administration and risk of patient non-compliance pose obstacles to achieving effective long-term therapeutic benefit. Identification of inflammatory targets that possess focused activity more acutely after MI may lend precision while limiting risks and costs of chronic long-term therapy.

¹University of Ottawa Heart Institute, Ottawa, Ontario, Canada. ²Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada. ³Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

⁴Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ⁵Department of Medicine and Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada. ✉e-mail: peter.liu@utoronto.ca

Ischemia triggers cardiomyocyte death and the rapid release of multiple danger signals that drive potent immune inflammatory responses through the activation of cytokines, notably members of the IL-1 or tumor necrosis factor (TNF) families and innate pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs)^{9–11}. Inflammatory signaling pathways are activated in a conserved manner by multiple PRRs or cytokines, and many of these factors have been implicated as contributors to post-MI pathology. For example, previous work from our laboratory and others using mouse models employing germline knockout of TNF and TLR signaling, including *Tnfa*^{-/-}, *Tlr4*^{-/-}, *Myd88*^{-/-} (a TLR adaptor protein) and *Irak4*^{-/-} (IL-1/Toll ligand receptor activated kinase 4) demonstrated reduced cardiac injury after MI^{12–14}. We hypothesized that identifying common, nodal regulators of these networks may uncover potential targets for inhibition of inflammation. Therefore, we searched for candidate molecules known to participate in their signal transduction.

Recently, employing an aptamer-based proteomics array, we identified in serum from a clinical cohort of patients with acute heart failure the distinct upregulation of cIAP2/baculoviral IAP repeat-containing 3 (*BIRC3*) that was consistent with elevation of standard cardiomyopathy biomarkers, including N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT). This was intriguing as cIAP2 upregulation is principally known as a cancer-associated event, and the protein was not known to be a cell-secreted factor. We subsequently identified *Birc3* as an early upregulated mRNA from extracted publicly available GeoSET data of mouse left ventricular infarct tissue¹⁵, coinciding with upregulation of a broad array of proinflammatory gene products known to be pathogenic in MI. cIAP2 is a RING (really interesting gene)-type E3 ubiquitin ligase, which is a closely related but distinct enzyme from cIAP1 (*Birc2*). cIAP proteins participate in signal transduction from PRR and TNF family cytokine receptors, where they participate in the regulation of cellular survival and differentiation as well as the coordination of inflammatory responses^{16–18}. After TNFR ligation, cIAP proteins are recruited by and interact with TNF receptor-activated factors (TRAF1 and TRAF2) and ubiquitinate key downstream kinases, including receptor-interacting protein kinase (RIPK)1 and NF-kappa B-inducing kinase (NIK)¹⁹. Ubiquitinated RIPK1 controls assembly of TNFR-stimulated death-inducing signaling complexes (DISCs) to promote cell survival²⁰. Ubiquitination of NIK promotes its degradation, thus preventing cleavage and activation of NF-kB2 (p100/52) to limit non-canonical NF-kB signal transduction²¹. cIAP proteins also interact with downstream ubiquitin ligases TRAF3 and TRAF6 after exposure to PRR agonists or TNF family cytokines^{22–25} and, in turn, modulate NF-kB and MAPK signaling.

The pro-survival and inflammation modulatory effects of cIAP proteins manifest themselves in various disease states, most prominently in several cancers where they are upregulated and act as

cooperating oncogenes²⁶. Although they possess high homology, expression of cIAP1 and cIAP2 is often distinct, where tissue distribution varies and cIAP2 has been shown to be uniquely regulated by NF-kB or stress-dependent stimuli²⁷. Control of cIAP protein expression is mediated by the second mitochondrial-derived activator of caspases (Smac)/Diablo protein²⁸. Peptido-mimics of Smac (Smac mimetics) are highly selective inhibitor of apoptosis (IAP) antagonists that promote protein degradation and sensitize cells to TNF family-dependent apoptosis²⁹. Smac mimetics are under evaluation for treatment of various cancers and exhibit a good safety profile to date^{30–32}. Here we report the discovery of cIAP2 upregulation after MI, where it differentially contributes to MI pathology relative to cIAP1. We further evaluated the source of this activity and found that hematopoietic expression of cIAP2 drives inflammatory response and, in turn, can be controlled using Smac mimetic compounds.

Results

An unbiased proteomics screen of plasma samples from patients with acute ischemic heart failure revealed increased levels of cIAP2 and distantly related *BIRC5* (Survivin) but not cIAP1 (Fig. 1a). We next identified that cIAP2 levels were increased in plasma from patients with acute MI compared to those with stable coronary artery disease (CAD) (Fig. 1b). cIAP2 was acutely increased in both human and mouse hearts after acute MI (Fig. 1c,d). Analysis of published microarray data from mouse heart subjected to ischemic infarction (*GSE4648*)¹⁵ showed a distinct expression pattern of cIAP2 relative to other *BIRC* protein members and consistently aligned with expression of other myeloid inflammatory gene transcripts acutely after MI (Extended Data Fig. 1a–e). Several cIAP2-associated Gene Ontology pathways were also upregulated (Extended Data Fig. 1f). In addition, knockout of *Nod1* (nucleotide-binding oligomerization domain protein 1), a microbial PRR known to recruit and activate cIAP1/cIAP2 (ref. 14), resulted in improved MI outcomes (Extended Data Fig. 1g), further implicating cIAP proteins as early mediators of injury and inflammation. Knockout of *Tnfrsf1a* (TNFR1/p55), *Tlr4* or *Nod1* reduced protein expression of cIAP1 and cIAP2 as well as that of inflammatory factors RIPK1, IRAK4 and TRAF6 after MI (Extended Data Fig. 1h).


The role of cIAP2 after MI was evaluated by comparing responses from cIAP2 germline knockout mice (*Clap2*^{-/-})²⁷ with those of *Clap1*^{-/-33} or C57Bl/6 (wild-type (WT)) mice subjected to coronary ligation. Histology of infarcted heart tissue demonstrated markedly reduced scar area in *Clap2*^{-/-} mice relative to *Clap1*^{-/-} and WT animals (Fig. 1e), whereas vascular immunohistochemistry demonstrated increased vascularization of injured tissue (Fig. 1f). Left ventricular end-diastolic and end-systolic dimensions were better preserved (Extended Data Fig. 2a); left ventricular ejection fraction was less severely impaired (Fig. 1g); and heart and lung weight/tibia ratios were reduced (Fig. 1h).

Fig. 1 | cIAP2 promotes injury following myocardial infarction. cIAP2 is upregulated and participates during cardiac injury after MI. **a**, SOMAScan measurement of cIAP2, Survivin (*BIRC5*), cardiac Troponin T (cTnT) and N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) plasma protein samples from acute heart failure patients ($n = 7$ measured at admission and D3 and D30 post-admission) and healthy controls ($n = 10$). **b**, ELISA of serum cIAP2 from percutaneous coronary intervention patients. Acute MI ($n = 9$) and CAD ($n = 12$). **c**, Immunoblot of human heart tissue lysates probed for IAP proteins cIAP2, cIAP1 and XIAP from healthy or ischemic cardiomyopathy patients. Vinculin was probed as an expression control. **d**, Immunoblot of cIAP1 and 2 isolated from mouse LV tissue lysates D1, D3 and D7 post-MI. β -tubulin served as an expression control. Immunoblot representative of two experiments. **e**, Masson's trichrome stained mouse midventricular heart sections (5 μ m thickness) D28 post-MI. Left: wildtype C57Bl/6J ($n = 7$). Middle: *Clap1*^{-/-} ($n = 6$). Right: *Clap2*^{-/-} ($n = 7$). Scale bars, 1 mm. LV scar area (collagen area – stained blue); morphometry of two representative slices per animal. **f**, Capillary density estimated by number of isolectin B4-positive (green) structures counted in LV MI border zone. Nuclei (DAPI) stained blue. Scale bars, 50 μ m ($n = 4$ per treatment

group). **g**, LV ejection fraction 28 days post-MI presented as % reduction from baseline (pre-MI) echocardiographic measurement. WT, $n = 10$; *Clap1*^{-/-}, $n = 6$; *Clap2*^{-/-}, $n = 10$. **h**, Heart and lung weights normalized to tibia length measured 4 weeks post-MI. Cont, $n = 6$ (WT), 4 (*Clap1*^{-/-}) and 5 (*Clap2*^{-/-}); MI-treated, $n = 15$ (WT), 10 (*Clap1*^{-/-}) and 10 (*Clap2*^{-/-}). **i**, Female mice: LV Ejection fraction. Left: WT ($n = 8$), *Clap2*^{-/-} ($n = 7$). Middle: heart weight:tibia length; sham-operated control WT ($n = 3$), *Clap2*^{-/-} ($n = 3$); MI, WT ($n = 7$), *Clap2*^{-/-} ($n = 7$). Right: lung weight:tibia length; sham-operated control WT ($n = 3$), *Clap2*^{-/-} ($n = 3$); MI WT ($n = 7$), *Clap2*^{-/-} ($n = 7$). **j**, LV MI border zone cell death (TUNEL-positive (red) staining) in 400 \times magnified 5 μ m heart sections. Nuclei (DAPI) stained blue. Triplicate fields counted per study specimen. Scale bar, 50 μ m; $n = 8$ (WT MI) and 7 (*Clap2*^{-/-} MI), respectively. Mouse data are aggregate from three experiments (male studies) or two experiments (female studies), respectively. Error bars, mean \pm standard deviation (s.d.); *P* values were calculated using two-sided *t*-test (**b,f,j**), one-way ANOVA with Dunnett's post-hoc test (**a**), one-way ANOVA with Bonferroni's correction (**e**) and two-way ANOVA with Bonferroni's correction (**g,h,i**). RFU, relative fluorescent units; Cont, control; D, day; HF, heart failure; ICM, ischemic cardiomyopathy; LV, left ventricular.

No sex-related differences were detected in the post-MI responses (Fig. 1i). Furthermore, *Clap2*^{-/-} mice showed reduced cardiomyocyte death in the peri-infarct border region acutely after MI (Fig. 1j), accompanied by reduced expression of apoptotic proteins annexin A1, cleaved poly-adenosine diphosphate (PARP) and cleaved caspase-8 (Extended Data Fig. 2b). At subsequent intermediate timepoints, we

observed reduced transcription of factors associated with adverse remodeling (for example, Nppb (brain natriuretic peptide), Myh7 (myosin heavy chain isoform 7), Tnfa and Tgfb1 in *Clap2*^{-/-} mice relative to WT controls (Extended Data Fig. 2c). Finally, expression of the alarmin high mobility group box 1 (HMGB1) and remodeling cytokine transforming growth factor beta 1 (TGFβ1) were reduced 28 days after



infarct in *Clap2*^{-/-} mice (Extended Data Fig. 2d). Overall, these findings demonstrate that cIAP2 expression contributes to enhanced cardiac injury after MI.

Hematopoietic-expressed cIAP2 drives post-MI inflammation

We assessed the requirement of cIAP2 acutely after MI for cardiac-specific immune cell infiltration and function. Heart histology showed reduced cellular inflammation in left ventricular myocardium of *Clap2*^{-/-} mice 3 days after MI (Fig. 2a). Cardiac inflammatory responses, demonstrated by left ventricular infiltrating neutrophils, Ly6C^{hi} monocytes and dendritic cells, were equivalent between WT and *Clap2*^{-/-} mice 1 day after MI (Fig. 2b); however, cellular infiltration became significantly and sustainably reduced in *Clap2*^{-/-} mice from day 3 after MI and as late as day 28 (Fig. 2b,c). Reduced infiltration, along with decreased transcription of inflammation-promoting chemokines Cxcl1 and Ccl2lf ventricular tissue of *Clap2*^{-/-} mice (Fig. 2d), indicated establishment of an attenuated inflammatory microenvironment. We evaluated the immune inflammatory role of cIAP2 by generating bone marrow chimeric mice to restrict cIAP2 deficiency to hematopoietic cells (Fig. 2e). Consistent with our findings in germline *Clap2*^{-/-} mice, *Clap2*^{-/-} chimeras showed reduced left ventricular scarring and improved ejection fraction at 28 days after MI (Fig. 2f,g). By contrast, *Clap1*^{-/-} chimeras demonstrated increased remodeling and worsened ejection fraction when compared to WT chimeric mice (Fig. 2g), supporting the hypothesis that cIAP2 plays a more prominent role in contributing to cardiomyopathy after MI. Although heart weights were relatively unchanged, *Clap2*^{-/-} chimeric lung weights were decreased relative to WT (Extended Data Fig. 3a), and *Clap2*^{-/-} chimeras demonstrated improved capillary density (Extended Data Fig. 3b). Cardiac immune infiltration was significantly reduced in *Clap2*^{-/-} chimeras (Extended Data Fig. 3c). In *Clap2*^{-/-} chimeric spleens, expression of immune regulator IL-10 was increased, whereas proinflammatory IL-23 was reduced (Extended Data Fig. 3d). We observed concurrent reduction of cardiac myeloid cells and lymphocytes, notably IL-17-expressing T cells that promote myocardial fibrosis and inflammation³⁴ (Extended Data Fig. 3e). Reverse chimeric mice (WT hematopoietic cells, *Clap2*^{-/-} resident tissues (Fig. 2h)) showed markedly increased scarring and reduced ejection fraction (Fig. 2i,j) as well as worsened cardiac remodeling, reduced vascularization and immune inflammation after MI (Extended Data Fig. 4). Collectively, these findings support the concept that the net cardioprotective effect of cIAP2 deficiency is principally caused by a reduction of hematopoietic-derived immune inflammation.

In patients who suffered recent MI, cIAP2 protein was upregulated in blood leukocyte isolates (Extended Data Fig. 5a, upper panel); similarly, cIAP2 protein levels were increased in mouse peripheral blood leukocytes 7 days after surgical MI (Extended Data Fig. 5a, lower panel). Leukocyte-isolated cIAP2 levels were higher in acute MI patient samples when compared to those with stable CAD, whereas cIAP1 levels were unchanged (Extended Data Fig. 5b). In the mouse model, we observed during the acute injury phase that *Clap2*^{-/-} mice exhibited significantly decreased circulating myeloid (CD11b⁺) cells but not lymphocytes (B or T cells), a deficit that widened by day 3 after injury (Extended Data Fig. 5c–e). We, therefore, investigated the hypothesis that the origin of this suppressed inflammatory response was an inhibition of myeloid cell production from hematopoietic producer sites in the spleen and bone marrow. Analysis of spleen and bone marrow cell numbers indicated that, in the early acute phase (24 hours) after MI, there was a net reduction in CD11b⁺ populations, which corresponded to increased infiltration to the heart (Figs. 2a and 3a,c). Although cell counts recovered progressively at day 3 after MI in both spleen and bone marrow, there was a protracted recovery in the spleen for *Clap2*^{-/-} mice relative to WT (Fig. 3a), which contrasted with the apparent full recovery of myeloid counts in the bone marrow (Fig. 3c). Overall, leukocytes were completely restored in both spleen and bone marrow of

WT and *Clap2*^{-/-} mice by day 28 after MI (Fig. 3b,d), suggesting that the impaired production of myeloid cells by *Clap2*^{-/-} mice was related to the inflammatory state after injury.

Biochemical analyses of the spleen after MI indicated an important role for cIAP2 in promoting inflammatory responses. Whole spleen lysates collected over time after MI showed that cIAP2 protein was progressively upregulated and correlated with reduction of TRAF3, a known protein degradation target of cIAP2 (Extended Data Fig. 6a). *Clap2*-deficient but not *Clap1*-deficient spleens showed preservation of TRAF3 and XIAP, an immune regulatory IAP protein (Extended Data Fig. 6b). Protein expression of nodal inflammatory regulators for both PRR and TNFR signaling (IRAK4, MyD88, RIPK1 and TRAF6) were all decreased in *Clap2*^{-/-} spleens at 7 days after MI (Extended Data Fig. 6c). cIAP2 co-immunoprecipitation with Traf3 was evident after MI injury (Extended Data Fig. 6d). cIAP2⁺ splenocytes showed increased proteolytic K48 ubiquitination of TRAF3 and activating K63 ubiquitination of RIPK1 (Extended Data Fig. 6e, upper panel). Although *Clap2* deletion did not affect the non-canonical NF-κB pathway in 24-hour post-MI splenocytes (Extended Data Fig. 6e, lower panel), nuclear localized canonical NF-κB factors p65/RelA and NF-κB1 (p50) were reduced in *Clap2*^{-/-} splenocytes as compared to WT mice 3 days after MI (Extended Data Fig. 6f). Furthermore, levels of Tnfa, Il1b and Il6 were reduced in *Clap2*^{-/-} spleens (Extended Data Fig. 6g). Altogether, these results suggest that cIAP2 is required for acute post-MI inflammatory responses by specifically modulating effector cells in the spleen (Extended Data Fig. 6h).

The response to MI from splenocytes is critical to maximal inflammatory activity and could be the culprit for worst-case cardiac outcome. It has been established that the spleen provides a critical reservoir of effector monocytes and other inflammatory cells that are rapidly mobilized to the ischemic myocardium^{35,36}. In *Clap2*^{-/-} mice, we observed reduced numbers of neutrophils and Ly6C^{hi} monocytes from spleens isolated 7 days after MI (Fig. 3e), which correlated with increased local splenocyte cell death (Fig. 3f). By contrast, splenic and cardiac levels of lymphocytes were unchanged throughout the acute post-MI phase (Extended Data Fig. 5e–g). These findings are consistent with the concept that cIAP2 permits splenic myeloid cell survival, which may support sustained heart inflammatory responses (Extended Data Fig. 5h). Aside from controlling NF-κB-associated inflammatory responses, cIAP proteins also suppress activation of TNF superfamily death complexes and, thus, can regulate apoptotic or inflammatory (necrotic) cell death³⁷. *Clap1/Clap2* deficiency in myeloid cells, including monocytes, results in cell death after exposure to TNF³⁸. cIAP2 also plays an important role in governing TNF-dependent survival and myeloid differentiation potential of hematopoietic stem cells³⁹. We found that, in contrast to 3 days after MI, Tnfa mRNA and protein levels were increased exclusively in spleen samples from *Clap2*^{-/-} mice after 7 days (Extended Data Fig. 7a,b). We additionally observed that protein expression of death ligand TRAIL (or TNFSF10/Apo2L) was increased in spleens but not in hearts of *Clap2*^{-/-} mice 3 days after MI (Fig. 3g). *Clap2*^{-/-} splenocyte TRAIL and TNF protein levels were increased 7 days after MI as were active forms of Caspase-8 and Caspase-3 and the apoptotic marker Annexin A1 (Extended Data Fig. 7b). TRAIL protein and its permissive transcription factor Interferon Response Factor 1 (IRF-1)⁴⁰ were increased in *Clap2*^{-/-} bone marrow cells (Extended Data Fig. 7c). Additionally, *Clap2*^{-/-} splenocytes upregulated TRAIL-R2/DR5, a TRAIL-binding death promoting receptor, as well as TNFR1, which can promote apoptosis in IAP-deficient cells (Fig. 3h). Immunohistochemistry showed that the numbers of TRAIL-expressing and DR5-expressing cells were both increased in *Clap2*^{-/-} spleens, with TRAIL⁺ cells found interacting with DR5⁺ splenocytes after MI (Fig. 3i and Extended Data Fig. 7d). Injection of TRAIL-neutralizing antibodies prevented splenocyte death in *Clap2*^{-/-} mice after MI (Fig. 3j). Finally, we confirmed that TRAIL expression is protective after MI, as antibody-mediated neutralization




Fig. 2 | Immune expression of cIAP2 increases post-MI inflammation. cIAP2⁺ hematopoietic cells promote injury and inflammation after MI. **a**, Inflammatory cell infiltrate 3 days post-MI in WT or *Clap2*^{-/-} mouse hearts. Full thickness 12.5× magnification; Scale bar, 1mm. Insets: 100× images. Imaging representative of three mice per treatment. **b,c**, Flow cytometric quantitation of LV inflammatory cellular infiltrate (neutrophils, Ly6Chi monocytes and CD11b⁺ dendritic cells) at (b) days 1, 3 and 7 and (c) day 28 post-MI. Controls: D1 (n=3); D3/7/28 (n=4). WT MI: D1 (n=3); D3/7/28 (n=6–9). *Clap2*^{-/-}: D1 (n=3); D3/7/28 (n=5–9). **d**, Quantitative PCR of Cxcl1 and Ccl2 (neutrophil and monocyte recruitment factors) measured in hearts of WT and *Clap2*^{-/-} mice 7 days post-MI; n=3 per group; transcripts normalized to β-actin. **e**, Generation of WT (CD45.1) recipient

bone marrow chimeric mice. **f**, LV scar area (blue) measured 28 days post-MI (n=6 from each treatment group). Scale bar, 1mm. **g**, LV ejection fraction from WT and *Clap2*^{-/-} and *Clap1*^{-/-}-chimeric mice 28 days post-MI. Controls: WT and *Clap2*^{-/-} (n=4); *Clap1*^{-/-} (n=2). MI: WT and *Clap2*^{-/-} (n=17); *Clap1*^{-/-} (n=4). **h**, Generation of reverse bone marrow chimeric mice (WT bone marrow donor to either WT or *Clap2*^{-/-} recipient mice). **i**, LV scar area from reverse chimeric mice; n=5 per treatment. Scale bar, 1mm. **j**, LV ejection fraction from control or MI-treated WT recipient and *Clap2*^{-/-} recipient mice. Controls: WT and *Clap2*^{-/-} (n=2). MI-treated, n=7 per group. Error bars denote mean ± s.d.; P values were calculated by one-way ANOVA with Bonferroni's correction (**b,c,g,j**), two-sided t-test (**d,f,i**). BM, bone marrow; BMT, bone marrow transplanted; i.v., intravenous.

of TRAIL enhanced cardiac injury and inflammation in both WT and *Clap2^{-/-}* mice (Fig. 3k and Extended Data Fig. 7e,f) and nullified protection associated with cIAP2 deficiency. These data collectively demonstrate that cIAP2 ablation increases splenocyte sensitivity to TNF-associated death signals, in part by upregulation of effector proteins such as TRAIL and DR5, contributing to the reduction of splenic inflammatory cell burden (Extended Data Fig. 7g).

cIAP inhibitory Smac mimetics are cardioprotective after MI

Our findings suggested that cIAP2 could be a pharmacologic target during the acute early phase after MI. We evaluated the monovalent Smac mimetic LCL161 as a model agent to assess the effect of cIAP inhibition after MI (Fig. 4a). In vivo, single 10 mg kg⁻¹ doses of LCL161 effectively degraded splenocyte cIAP1/cIAP2 (Fig. 4b) and reduced levels of circulating blood neutrophils and inflammatory Ly6C^{hi} monocytes (Extended Data Fig. 8a), effects achieved at five-fold lower doses than required for mouse tumor regression²⁹. By contrast, LCL161 had no effect on cardiac cIAP protein levels at doses lower than tolerance limits from phase I clinical trial evaluation⁴¹. Pretreatment of ex vivo bone marrow-derived dendritic cells with LCL161 reduced broad K63 ubiquitination as well as expression of IRAK4, MyD88 and RIPK1 in response to stimulation by freeze-thaw heart lysate (Extended Data Fig. 8b). Mice subjected to MI were administered LCL161 at 1 day and 4 days after MI (Fig. 4c). Compared to mice receiving vehicle control, LCL161-treated mice exhibited significantly reduced mortality after MI (Fig. 4d). LCL-treated mice also exhibited reduced left ventricular scarring, heart weight and left ventricular remodeling accompanied by improvement in left ventricular ejection fraction (Fig. 4e–h). LCL161 treatment also reduced cardiac immune infiltration after MI (Fig. 4i and Extended Data Fig. 8c,d). cIAP2 serves as the principal inflammatory target after MI, evidenced by the differential outcomes achieved by LCL161 in *Clap1^{-/-}* MI-operated mice compared to *Clap2^{-/-}* mice (Extended Data Fig. 8e). Cardiac expression of remodeling and inflammatory genes was lower in LCL161-treated mice relative to vehicle controls 28 days after MI (Fig. 4j and Extended Data Fig. 8g).

Single administration of LCL161 24 hours after MI was also cardioprotective when assessed at 7 days, as demonstrated by reduced early scar formation, improved left ventricular ejection fraction and reduction of heart weight as well as reduction of cardiac inflammatory cells (Fig. 5a–c). Consistent with the effect of cIAP2 deficiency, myeloid inflammatory cell numbers were reduced in the spleens of LCL161-treated mice 7 days after MI (Fig. 5d). Overall, cardiac transcription of inflammatory and remodeling genes was unchanged in LCL161-treated mice relative to vehicle controls, with the exception of mRNA for key inflammatory chemokine Ccl2 and its receptor Ccr2 (Fig. 5e). Further evidence of LCL161 effectiveness to reduce cIAP inflammatory activity was revealed by increased TUNEL staining selectively in splenocytes, concomitant with greater expression of TRAIL in LCL161-treated MI-operated mice (Fig. 5f,g). Critically, and

in agreement with a dependence on persistent inflammatory state to influence cell fate, numbers of splenic and bone marrow leukocytes had rebounded by day 28 after MI (Extended Data Fig. 8h). Altogether, our results demonstrate a critical role for cIAP2 in maintaining a maximal inflammatory response in mice after MI. This response is mediated by cIAP2 control over cell death signaling to promote increased survival of myeloid cells, the importance of which being demonstrated by the protective inflammatory cell-reducing effects after MI of cIAP-inhibitory Smac mimetic compounds.

Discussion

Mortality rates from acute MI are in steady decline^{42,43}; however, ischemic heart disease remains the primary cause of non-infectious death^{1,44}. Survivors of ischemic injury are prone to chronic inflammatory disease and increased risk of subsequent cardiovascular events or heart failure^{2,45,46}. Additionally, patient quality of life is markedly diminished with severity of patient-reported impact related to prognosis⁴⁷.


Increasing attention and research focus have been directed to the inflammatory response after MI. It has been established that increased systemic inflammation is present after acute ischemic cardiac injury, with a strong myeloid inflammatory component^{48–50}. Prognosis is also negatively influenced by sustained elevation of circulatory leukocytes^{45,51}. Clinical investigation has highlighted the exciting potential of anti-inflammatory therapies to improve acute outcomes after MI^{6–8}. However, results are mixed when the treatments are administered in the chronic phase after MI; although the studies established proof of concept, the agents were associated with increased risk of infection. Therefore, we searched for candidate inflammatory modulators that can be targeted earlier after MI to more effectively recalibrate the downstream chronic inflammatory response. Multiple key innate pattern recognition receptors and pro-inflammatory cytokine receptors are activated after MI⁹, and signal transduction pathways initiated by these molecules show redundancy and conservation, notably in the activation of transcription factors such as NF-κB. TLR, NLR as well as TNF and IL-1 receptors commonly recruit cIAP1 and cIAP2–RING-type E3 ligases that regulate cell survival and inflammation^{52,53}. Impairment of cIAP protein pro-survival function has been the dominant rationale in developing inhibitory small-molecule strategies for the treatment of malignancies that may feature their overexpression^{26,54}.

This study suggests that cIAP2 plays a critical role as a regulator of innate inflammatory cells, where its loss of expression after MI results in reduced cell accumulation in the heart while also reducing cellular burden in the spleen. The spleen is an important source of inflammatory cell mobilization after MI^{55,56}, and this systemic reservoir can incite further chronic inflammatory consequence if left unregulated⁵⁷. Although hematopoiesis plays an important role in the maintenance of chronic inflammatory states, we postulate that, in the setting of cIAP2 deficiency, the key therapeutic effect is upon cell death, particularly of myeloid cells. This is because of the well-described importance of

Fig. 3 | Reduction of inflammatory cells in *Clap2^{-/-}* MI-operated mice.

Increased TRAIL and DR5 expression in *Clap2^{-/-}* splenocytes after MI. **a**, Left: flow cytometric quantitation of myeloid (CD11b⁺) cells at D3 post-MI spleen samples from WT and *Clap2^{-/-}* mice. Right: dot plots correspond to representative D1 and D3 post-MI samples, representative of aggregate data from three experiments. **b**, Quantitation of splenic myeloid (CD11b⁺) cells D28 post-MI; (controls $n = 3$; MI, WT $n = 10$; *Clap2^{-/-}* $n = 7$). **c**, Left: flow cytometry of myeloid (CD11b⁺) cells at D3. Right: dot plots correspond to representative D1 and D3 post-MI samples. **d**, Bone marrow myeloid cells measured D28 post-MI from WT and *Clap2^{-/-}* mice. **e**, Flow cytometry of spleen neutrophil and Ly6Chi monocytes D7 post-MI of WT (C57Bl/6) or *Clap2^{-/-}* mice; (controls $n = 3$; WT $n = 7$; *Clap2^{-/-}* $n = 5$ mice per group). **f**, Spleen TUNEL+ staining D3 post-MI; (controls $n = 4$; WT MI $n = 7$; *Clap2^{-/-}* MI $n = 5$. 400× magnification; scale bar, 50 μm). **g**, Increased TRAIL+ staining of splenocytes from *Clap2^{-/-}* mice D3 post-MI. Low to undetectable TRAIL staining in matched heart samples. Scale bar, 50 μm; (control $n = 4$;

WT $n = 7$; *Clap2^{-/-}* $n = 5$). **h**, Left: immunoblotting of spleen DR5 (TRAIL-R2) and TNFR1 expression D3 post-MI. Image representative of two similar immunoblots. Right: immunofluorescence microscopy of splenic DR5 (TRAIL-R2) expression. Images representative of three mice per group. Scale bar, 25 μm. **i**, High resolution AiryScan images of splenocytes from WT (top) and *Clap2^{-/-}* (bottom) mice D3 post-MI. Immunostaining for TRAIL (green) and DR5/TRAIL R2 (violet). DAPI (blue), nuclei. Scale bar, 5 μm. Imaging representative of three animals per treatment group. **j**, TUNEL+ splenocytes reduced D3 post-MI in *Clap2^{-/-}* mice injected with anti-TRAIL neutralizing antibody. Image representative of three animals per treatment. Scale bar, 50 μm. **k**, LV ejection fraction and heart weight:tibia length of mice D28 post-MI following TRAIL neutralizing antibody injection. Error bars denote mean ± s.d.; *P* values were calculated by one-way ANOVA with Bonferroni's correction (**e,f,g**), two-way ANOVA with Bonferroni's correction (**a,c,k**).






Fig. 4 | Smac mimetic LCL161 reduces cardiac injury following MI. Smac mimetic LCL161 is cardioprotective after MI. **a**, LCL161 stimulates degradation of cIAP1/2. **b**, In vivo cIAP1/2 degradation in spleen and heart tissues following dose titration of LCL161. Immunoblot representative of two similar experiments. **c**, Strategy for LCL161 administration following MI. **d**, Kaplan–Meier survival analysis of mice subjected to MI receiving vehicle or LCL161 gavage. Vehicle-treated controls, $n = 18$ mice (start of experiment); LCL161-treated controls, $n = 15$ mice (start of experiment). **e**, LV scar area of MI-operated mice receiving vehicle control (top) or LCL161 (10 mg kg^{-1} , bottom); $n = 7$ per group. Scale bars, 1mm. **f**, Heart weight:tibia length D28 post-MI. **g**, LV end systolic diameter and measurements taken D28 post-MI. **h**, LV ejection

fraction measured D28 post-MI. Control operated mice, $n = 7$ (3 LCL-treated, 4 vehicle treated); MI-operated mice, $n = 10$ vehicle treated, $n = 11$ LCL161-treated. **i**, Flow cytometry of heart infiltrating neutrophils, Ly6Chi monocytes and dendritic cells D28 post-MI. Control-operated mice, $n = 3$ (two vehicle-treated, one LCL161-treated); MI-operated mice, $n = 6$ per group. Data aggregate from three experiments (**d–i**). **j**, Quantitative PCR of remodeling gene products D28 post-MI; $n = 4$ per MI treatment group. Error bars denote mean \pm s.d.; P values were calculated using Gehan-Breslow-Wilcoxon test (**d**), two-sided t -test (**e, j**), one-way ANOVA with Bonferroni’s correction (**f, g, h, i**). LCL, LCL161; LVESD, left ventricular end-systolic diameter; Veh, vehicle.

cIAP proteins, particularly cIAP2, to promote myeloid cell survival in response to MI-relevant inflammatory ligands such as TNF or agonists of TLRs^{38,53,58}. Our findings show that cIAP2 deficiency or cIAP ablation induced a marked reduction of myeloid cells, concomitant with lowered cardiac inflammation and overall attenuated inflammatory cellular signaling in the acute phase after MI. The viability of cIAP2 as an early target for such an acute, aggressive injury is evident by the observation that the overall immune system response returned to a balanced state in latent timepoints. With relevance to the death-inducing effect of cIAP2 deficiency, we found elevated expression of pro-apoptotic TNF family factor TRAIL⁵⁹ after MI in *Clap2*^{-/-} mice. Upregulation of the mouse

ortholog of TRAIL-selective death receptor DR5 (TRAIL-R2) was also observed, which is known to be an essential permissive step for TRAIL bioactivity during many apoptotic cell responses⁶⁰. In cardiovascular disease, TRAIL expression infers protective effects, as high serum levels of TRAIL are associated with favorable outcomes^{61,62}, whereas circulatory (soluble) DR5 predicts increased mortality⁶³. However, its role in the heart after injury remains poorly understood. In vivo studies have suggested disparate effects of TRAIL activity. Acute blockade of DR5 reduced myocardial ischemia–reperfusion injury⁶⁴; conversely, agonists of DR5 reduced cardiac injury and remodeling in a chronic injury model⁶⁵.




Fig. 5 | LCL161 induces splenic cell death and TRAIL expression. **a**, Single dose regimen for mice with LCL161. **b**, Masson's trichrome staining of hearts showing reduced LV scar formation at D7 post-MI following single dose LCL administration of mice, with accompanying improvement in ejection fraction and reduction in heart weight normalized to tibial length. Scale bars, 1 mm; $n = 3$ per group. **c**, Reduction of immune infiltration at D7 post-MI following single dose LCL gavage. Controls, $n = 3$; MI-operated, $n = 6$ per group. Data are aggregate of two representative experiments. **d**, Flow cytometric measurement

of spleen neutrophils and Ly6Chi monocytes D7 post-MI. $n = 4$ mice per group. **e**, Quantitative PCR measurement of representative inflammatory transcripts normalized to HPRT from spleens D7 post-MI. $n = 3$ mice per group. **f**, increased TUNEL+ splenocytes in LCL-treated mice D7 post-MI. Scale bars, = 50 μ m. Vehicle treated, $n = 6$; LCL-treated, $n = 5$. **g**, Immunofluorescence microscopy showing TRAIL+ staining of splenocytes from mice 7 days post-MI. Scale bars, 25 μ m; $n = 5$ mice per group. Error bars denote mean \pm s.d.; P values were calculated using two-sided t -tests.

Expression of mouse TRAIL and its receptor is widely distributed in the body. Consistent with other TNF ligands, it possesses pleiotropic functions, including regulation of NF- κ B-dependent inflammation. Notably, TRAIL appears to demonstrate an ability to selectively induce apoptosis, typically sparing healthy or non-malignant cells in various studies⁶⁶. Thus, it is possible that cellular fates in response to TRAIL activation are dependent upon the tissue environment or cell type being targeted. Acutely after MI, TRAIL expression is upregulated in the spleen but not in cardiac left ventricular tissue of *Clap2*^{-/-} mice, suggesting that a critical site for inflammatory suppression is the spleen, consequently reducing supply of inflammatory cells to the heart. Antibody neutralization of TRAIL notably increased levels of inflammation

and impacted cardiac function in both WT and *clAP2*-deficient mice after MI, although we could not evaluate the effect of TRAIL neutralization in the acute post-MI heart. A limitation of using such strategies is the potential for generalized immunomodulation associated with administration of bulk IgG in technical control animals, thus potentially reducing the biological effects of the injury⁶⁷. Use of activators or antagonists of DR5 could, in this context, be very informative to the role of TRAIL during the overall post-MI response.

Consistent with the above observation is the potent degree of anti-inflammatory activity mediated by the IAP antagonist LCL161 (a Smac mimetic) after MI. Smac is an evolutionarily encoded IAP inhibitor⁶⁸ and is the template for many compounds now in clinical

development for cancer treatments⁶⁹. Smac mimetics show variable levels of inhibition of cIAP1, cIAP2 and XIAP; however, there are differences in their inhibitory potency and/or their degradative capacity against the enzymes^{70,71}. Molecular studies suggest that efficient degradation of cIAP proteins is strongly dependent upon expression of cIAP1 (ref. 72), which tends to be expressed more broadly across cell and tissue types and at more stable levels. By contrast, cIAP2, although highly homologous in sequence and structure to cIAP1, is a stress-responsive member of the IAP gene family^{26,53}. This property may explain, in part, why our treatment, when applied early after MI, was effective to produce a lasting effect on cardioprotection. Transient ablation of cIAP2 (along with cIAP1) can potentially reduce acute inflammation; therefore, avoidance of continuous administration may subsequently reduce the potential toxicity of the Smac mimetic. IAPs are known to play protective roles in resident tissue cell types after injury⁷³⁻⁷⁵. We established through dose titration of LCL161 that IAP inhibition could be achieved in splenocytes without impacting the protein levels in cardiac tissue, with protein degradation observed at quantities lower than predicted to be safely effective clinically. As evidence of broader immunomodulatory potential, leukocyte studies have demonstrated beneficial activity for Smac mimetics in the treatment of inflammatory bowel disease⁷⁶ and a mouse model of pneumonia⁷⁷. Ultimately, irrespective of the promise of these agents, further study is needed to confirm sparing of non-target organs and cellular effectors with cIAP inhibitory strategies.

In summary, we highlight cIAP2 as a potent proinflammatory factor that plays a critical role in maintaining cardiac inflammatory cell supply after MI. Cardiac injury and function are improved when hematopoietic expression of cIAP2 is ablated, and this protective effect is reproduced using a clinically relevant cIAP antagonist, LCL161. We propose that cIAP2 inhibition is an important new immunomodulatory strategy for improvement of cardiac outcomes after MI.

Methods

Human samples

Patient samples (blood whole plasma, peripheral blood mononuclear cells (PBMCs) and whole unfractionated leukocyte lysates) were obtained with consent and used under approval from the Ottawa Health Science Network Research Ethics Board (OHSN-REB protocols no. 20140869, no. 20150428 and no. 20160516-01H). Patient characteristics are summarized in Supplementary Table 1. For whole plasma cell-free protein analysis, samples were isolated from $N = 7$ randomized patients presenting with acute heart failure at the time of admission and subsequently at days 3 and 30 after admission and compared with $N = 10$ healthy controls. Analyses were screened using a SomaScan aptamer-tagged proteomics array (SomaLogic) as described previously⁷⁸. Plasma was frozen until analysis at -80°C . Acute MI versus CAD PBMC analyses were conducted using isolates from patients admitted to the University of Ottawa Heart Institute percutaneous coronary intervention clinic, where approximately 30 ml of whole blood samples was obtained within 2 hours of admission (for planned CAD intervention, $N = 12$) or diagnosis of ST-segment elevated MI (STEMI, referred to as 'MI', $N = 9$). PBMC isolates were performed by gradient centrifugation of PBS-diluted whole blood over a 2:1 (v/v) Percoll gradient at 675g for 30 minutes at room temperature, followed by concentration of buffy coat cell content in RPMI 1640 + 5% (v/v) FBS (Thermo Fisher Scientific) to a final concentration of 5×10^6 cells per milliliter. Standardized quantities of cells (1×10^6 per milliliter per sample) were reserved for flow cytometric analysis. For collection of cell lysate from unfractionated leukocytes, patient samples were collected at the time of clinical assessment, followed by removal of red blood cells using hypotonic ammonium chloride/potassium bicarbonate buffer and subsequent lysis of nucleated cell pellets. Lysates were stored for use in immunoassays. Patient sera were collected from patients with MI versus patients with CAD by centrifugation of 2 ml of whole blood at 1,000g

at room temperature, followed by extraction of aqueous (non-packed hematocrit) fraction. Sera were stored for analysis at -80°C .

Mouse post-MI gene set enrichment analysis

Left ventricular expression of gene products over a 48-hour time-course was catalogued in the National Center for Biotechnology Information (NCBI)-curated, open-source dataset GSE4648 (GDS2329) (for reference, see <https://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS2329>). The dataset was uploaded onto the Salk Institute open-access R Shiny bioinformatics platform BART (Bioinformatics Array Research Tool)⁷⁹, and data were organized and catalogued using applications encoded in the software package ($N = 2$ per MI timepoint in infarcted left ventricular region or $N = 2$ for controls at representative timepoints). Data for differential gene expression and Gene Ontology annotation were collected from the 24-hour post-MI timepoint, and the summary of differential genes is located in Supplementary Tables 2 and 3. Statistical analyses were conducted within the software application.

Animals

C57Bl/6 (WT), *Ciap2*^{-/-}, *Ciap1*^{-/-}, *Nod1*^{-/-}, *Tlr4*^{-/-} and *Tnfrsf1a*^{-/-} mice were bred and co-housed for multiple generations under identical specific pathogen-free conditions (including consistent chow, water and air supply) in the University of Ottawa Heart Institute vivarium prior to experimental procedures. Prior to breeding and use in this study, the principal experimental mouse strains *Ciap2*^{-/-} and *Ciap1*^{-/-} were similarly normalized to C57Bl/6 background by backcrossing as described in ref. 27 and ref. 33, respectively. Bl/6 CD45.1 mice (B6.SJL-*Ptprc*^a*Pepr*^b/BoyJ) were purchased from The Jackson Laboratory. Mice were 12–16 weeks of age prior to surgical experiments. Mice were kept on a consistent 6:00–20:00 light/dark cycle, at constant 22°C temperature and 40% humidity and were provided chow and drinking water ad libitum. Both male and female mice were used for experimental MI procedures for germline knockout *Ciap2*^{-/-} studies; otherwise, males were used in reported experimental work. In all experiments, groups of animals were operated on in random order, and assignment to either experimental MI or control surgery was conducted in a blinded fashion. All animal experimentation was conducted under the guidance and with approval of the University of Ottawa Animal Care Committee (ACC), with experimental work adhering to ACC animal usage protocols H1b-2218, H1b-3536, H1e-2246 and H1e-3727. All surgical procedures were carried out with strict adherence to university-mandated protocols, including perioperative and postoperative analgesia and wellness assessment. Experiments were conceived and conducted to ensure compliance with directives from the Canadian Council for Animal Care and the ARRIVE criteria for responsible animal research.

MI

Male or female mice, aged 12–16 weeks, were randomly assigned to MI or sham (control) surgery. One hour prior to surgical procedure, mice were injected subcutaneously with a 1.2 mg kg⁻¹ solution of buprenorphine slow-release formulation and a 1.0 mg kg⁻¹ solution of meloxicam. Mice were anesthetized with 2–4% isoflurane (mixed with O₂); hair on the left chest was removed with a depilatory cream; and mice were intubated with a 20-gauge soft catheter attached to a ventilator operating at 130–150 strokes per minute. Once in adequate anesthetic surgical plane, the chest was opened on the left rib cage between either the 4th or 5th intercostal space; the pericardium was disrupted; and the left anterior descending artery (LAD) was located and ligated with a 7-0 silk suture approximately 2 mm below the atrial appendage. Arterial occlusion was verified by blanching of the distal myocardial tissue, at which time the chest was closed with a 6-0 Surgipro polyvinyl suture. Sham-operated controls underwent the same procedure foregoing the terminal LAD ligation. The animals were allowed to recover from anesthetic in a 30°C hyperbaric incubator and received

1.0 mg kg⁻¹ meloxicam daily for two subsequent days. Food and water were not withdrawn at any point prior to or after surgery. Mice were subsequently monitored for the duration of the experimental protocol, determined at random to last 1, 3, 7 or 28 days unless endpoint was determined by wellness assessment.

Isoproterenol treatment

Twelve- to 16-week-old male C57Bl/6 mice were injected subcutaneously (subscapular) with 10 mg kg⁻¹ isoproterenol-HCl in saline. Twenty-eight days after injection, cells and protein lysates were isolated and used in flow cytometry or immunoblotting assays.

Blood, spleen, bone marrow and heart immune cell isolation

PBMCs. Whole blood (50–100 µl) was collected by temporal vein lancet puncture and lysed with 20 volumes (1–1.5 ml) of cold red blood cell lysis buffer (150 mM ammonium chloride (NH₄Cl), 20 mM potassium carbonate (K₂HCO₃) and 0.1 mM EDTA). Suspensions were centrifuged at 330g, and non-lysed cell pellets were resuspended in either PBS supplemented with 1% BSA for flow cytometry analyses or cell lysis buffer (PBS supplemented with 1% (v/v) Triton X-100, 0.25% (v/v) sodium deoxycholate, 5 mM EDTA, 10 mM sodium orthovanadate, 2 mM sodium fluoride and 1× concentrated cOmplete protease inhibitor cocktail).

Spleens. Whole spleens from sham or MI-treated mice were excised, washed in cold sterile PBS and disrupted by crushing through 40-µm nylon mesh strainers. Cells were then centrifuged at 330g and resuspended in red blood cell lysis buffer. Non-lysed cells were centrifuged at 330g, and cell pellets were resuspended in PBS plus 1% BSA (for flow cytometry), RPMI 1640 + 5% FBS (for adoptive transfer) or cell lysis buffer (for immunoblot protein analyses).

Bone marrow. Long bones (either tibia or femurs) were excised; muscle and connective tissues were removed; and bones were washed in cold 70% ethanol and PBS, consecutively. Bones were then crushed using a mortar and pestle. Marrow was resuspended in cold PBS and passed through a 40-µm nylon strainer, and cell suspensions were centrifuged at 330g, followed by resuspension in PBS/1% BSA, RPMI 1640 + 5% FBS or cell lysis buffer as above.

Hearts. Hearts were excised and flushed with cold PBS, and left ventricular tissue was dissected. In preliminary experiments where both MI or isoproterenol treatments were evaluated, the apical (approximate lower third) region was removed, and cells were isolated; in focused MI experiments, the infarct-affected (border) region, which we defined as the approximate 2-mm boundary on either side of the infarcted region (identified by fibrosis or blanching of the myocardium), was removed and used for cell isolation and flow cytometry or for whole-tissue molecular analyses (RT-qPCR or immunoblotting; Supplementary Fig. 1). Left ventricular tissue extracts were weighed and digested in tissue digestion buffer (113 mM NaCl, 0.6 mM KH₂PO₄, 0.6 mM Na₂HPO₄, 20 mM HEPES, 20 mM NaHCO₃, 4.7 mM KCl, 2 mM MgCl₂, 1 mM EDTA, 60 U ml⁻¹ DNase I (MilliporeSigma), 100 U ml⁻¹ hyaluronidase (MilliporeSigma), 450 U ml⁻¹ Collagenase I (Worthington Biochemical), 250 U ml⁻¹ Collagenase II (Worthington Biochemical) and 125 U ml⁻¹ Collagenase D (Worthington Biochemical)) by shaking at 37 °C for 1 hour. Liberated cells were gravity filtered through a 40-µm nylon strainer by washing with cold PBS. Cell suspensions were centrifuged at 330g and resuspended in either PBS/1% BSA or RPMI 1640/5% FBS. For quantitation purposes, aliquots of all cell suspensions (prior to red blood cell lysis or centrifugation) were collected; 1 in 10 dilutions were made in PBS; and cells were counted using a hemocytometer.

Flow cytometry and fluorescence-activated cell sorting

Cell isolates collected as described above were stained with specific antibody cocktails at a concentration of approximately 2.5 × 10⁶

cells per milliliter in PBS supplemented with 1% BSA for 90 minutes on ice protected from light. Antibody concentrations were prepared as master cocktail mixes with specific antibodies employed at the concentrations indicated in Supplementary Table 4. For cytometric analysis, stained cells were washed with PBS, spun down at 330g and resuspended in PBS supplemented with 1% v/v paraformaldehyde. Stained cells were either immediately analyzed or stored overnight at 4 °C protected from light. Gating strategies for cytometry experiments are provided in the Supplementary Data file. For fluorescence-activated cell sorting (FACS) purification and cell recovery, stained cell isolates were washed, resuspended in RPMI 1640/5% FBS and immediately resolved. Cells were collected into chilled 5-ml round-bottom polypropylene tubes containing 1 ml of RPMI 1640/5% FBS. Where possible, cell purifications were verified by performing reanalysis on aliquots of recovered sample or by microscopic assessment on a hemocytometer. All cytometric processing was carried out on a FACSriaIII four-laser cell sorter/cytometer (BD Biosciences). Experiments were acquired using BD FACSDiva version 8.2 software, and analysis was performed using either FACSDiva or FlowJo version 10.8 software (Tree Star).

Bone marrow transplantation

Bone marrow chimeric mice were established by lethally irradiating 6–8-week-old B6 CD45.1 mice with exposure to two cycles (spaced by 20-minute intervals) of 450-cGy gamma irradiation using a Gammacell 3000 Cesium¹³⁷ source irradiator (Best Theratronics). Within 3 hours of irradiation, mice were injected intravenously with 2.5 × 10⁶ sterile-isolated, filtered bone marrow cells from C57Bl/6, *Clap2*^{-/-} or *Clap1*^{-/-} donors. Mice were allowed to recover over a minimum 6-week period in a sterilized housing unit, after which a blood sample was collected to assess hematopoietic reconstitution by flow cytometric analysis of CD45.1 (recipient strain) and CD45.2 (donor strain) isotypes as well as verification of PBMC populations. Chimerism of 90% or greater was consistently achieved, with no apparent deficiency in specific cell populations. Animals were subsequently randomized into MI experiments, with sample groups aggregated from three separate similar experimental protocols. In all experiments, small groups of mice were randomly assigned to sham surgical procedure. For 'reciprocal' bone marrow transplantation experiments, CD45.2 (C57Bl/6 or *Clap2*^{-/-}) mice were irradiated and served as recipient strains for CD45.1 bone marrow donation in order to assess the role of resident cardiac cIAP2 expression after injury. Experiments were presented as aggregate data from two similar experimental protocols.

Antibody injections for in vivo neutralization studies

TRAIL (Tnfsf10) neutralization using N2B2 monoclonal antibody. C57Bl/6 or *Clap2*^{-/-} mice (as above) were injected with either 250 µg of rat anti-TRAIL IgG2a(κ) monoclonal antibody (clone N2B2; BioLegend, 109308) or equivalent quantity of isotype control rat IgG2a (clone RTK2758; BioLegend, 400502) via intraperitoneal injection 3 days before surgery, perioperatively or 3 days after surgery. Apoptosis in spleens of MI-operated mice was evaluated in a subgroup of animals at 3 days after MI, and the remaining animals were euthanized at day 28 for assay of cell infiltration or cardiac injury, as indicated in Fig. 3j,k and Extended Data Fig. 7e,f.

Smac mimetic treatments

The monovalent Smac mimetic LCL161 was purchased from Selleck Chemicals. For in vitro experiments, LCL161 was dissolved in dimethylsulphoxide (DMSO) and used at 5-µM concentrations applied to cultured bone marrow-derived dendritic cells (described below) for 48 hours in the presence or absence of inflammatory stimulation. Control cultures were treated with DMSO only. For in vivo experiments, mice were first weighed and then administered 10 mg kg⁻¹ LCL161 dissolved in sodium acetate buffer (0.07 M NaOAc, 0.03 M HCl (pH 4.6))

orally by intragastric gavage at day 1 or days 1 and 4 after MI. Control mice were gavaged with acetate buffer only. Animals were monitored for up to 7 days or 28 days after MI, as indicated.

Echocardiography

Mice were sedated with 1.5% isoflurane (per liter O₂), and hair was removed from the left chest. Parasternal long axial (high resolution, electrocardiogram-gated kilohertz visualization (EKV) and low resolution, B mode) and short axial (M mode) images were collected using a Vevo 770 or a Vevo 3100 ultrasound imaging station (FUJIFILM/VisualSonics). Systolic function (ejection fraction and stroke volume) was estimated by the observed change in two-dimensional area measurements of endocardial wall from end-diastole to end-systole using parasternal long axis (planar projection of whole ventricle from aortic valve to apex) high-resolution (300 images per beat) EKV image analysis; dimensional change and myocardial wall thickness were estimated by linear measurement of midventricular chamber from anterior to posterior wall in short axial (vertical projection) images. Imaging was performed by a blinded operator, and image analysis was carried out in random order by a blinded investigator. Measurement and calculation of imaging results was performed with Vevo LAB software (version 3.0-770 or version 3.1.1).

Histology

Hearts were excised, flushed with cold PBS and immersed in 0.5 M KCl for 5 minutes to enhance ventricular dilatation. Subsequently, hearts were fixed in 20 volumes (approximately 3 ml for mouse hearts) of 4% paraformaldehyde for 24–48 hours, reimmersed in PBS for another 48 hours and then equilibrated in autoclaved water and stored at 4 °C until being embedded in paraffin. For tissue sectioning, full thickness (concentric) 5- μ m sections were cut using a microtome and collected onto slides. Tissue sections were deparaffinized using toluene and rehydrated by immersion in stepwise decreasing ethanol gradients and then subjected to hematoxylin and eosin staining, Masson's trichrome or immunofluorescence microscopy. Midventricular sections corresponding to regions spanning the infarction were selected (based upon presence of silk suture fibers from LAD ligation; approximately similar tissue regions were selected from sham-operated mice) and used for analysis.

Tissue morphometry

Serial midventricular sections from MI-treated or sham-operated mouse hearts were stained with Masson's trichrome (to expose collagenous scar tissue, stained blue), and collagen area was estimated as a fraction of whole left ventricle by blinded measurement using ImageJ (version 3) open-source software (National Institutes of Health). Mean area calculations from each subject were used to estimate scar area, where a minimum of five animals per MI treatment group were used for measurement.

Cell culture experiments

Reagents were purchased from Thermo Fisher Scientific unless otherwise indicated. Isoproterenol-HCl was purchased from MilliporeSigma. iE-DAP and poly I:C were purchased from InvivoGen. Flt3 ligand (Flt3L) was purchased from R&D Systems/Bio-Techne. Bone marrow-derived plasmacytoid dendritic cells: Whole bone marrow was isolated from long bones as described, and 2 \times 10⁶ cells per milliliter were seeded into 12-well culture dishes (500 ml per well) with RPMI/5% FBS supplemented with 50 ng ml⁻¹ Flt3L and re-fed every third day for 7 days. The final 3 days, cells were additionally administered 5 μ M poly I:C to further mature the cell populations⁸⁰. Cells were subsequently stimulated with 10 μ M iE-DAP and 20 μ g necrotic heart tissue. Following 48 hours, cultured cell lysates were collected and immunoblotting was performed for proteins as presented in as presented in Extended Data Fig. 8b.

Immunofluorescence microscopy

Formalin fixed, paraffin-embedded heart midventricular sections were deparaffinized, and antigen retrieval was performed by either a 15-minute incubation in 1 \times proteinase K at 37 °C (for TUNEL staining or intracellular antigen staining) or a 10-minute steaming at 65 °C with 10 mM sodium citrate buffer (for surface antigen staining or isolectin B4 staining). TUNEL assay was conducted using a Click-iT EdU kit (AlexaFluor 594) (Thermo Fisher Scientific) according to the manufacturer's specifications with nuclear counterstaining using DAPI. For immunostaining, sections were blocked for 30 minutes with 2% normal goat or donkey serum (see below) in PBS. Primary antibodies (Supplementary Table 5) were incubated with sections using indicated dilutions overnight at 4 °C, followed by washing with PBS plus 0.05% (v/v) Tween 20 detergent. Secondary antibodies (goat anti-mouse or donkey anti-rabbit) conjugated to various AlexaFluor fluorochromes were used at reported dilutions in the appropriate blocking buffer (determined by host species) and incubated on sections at room temperature for 90 minutes, followed by washing with PBS 0.05%/ Tween 20 and PBS, sequentially. Staining of myocardial vasculature was performed using *Griffonia simplicifolia* isolectin B4 conjugated with AlexaFluor 488 (Thermo Fisher Scientific) at a concentration of 1 μ g ml⁻¹ (diluted in 10 mM MgCl₂/MnCl₂/CaCl₂) overnight at 4 °C and counterstained with DAPI. Slides were mounted with ProLong Antifade Gold (Thermo Fisher Scientific). The photomicrographs were captured in a blinded fashion using an Olympus IX81 laser confocal microscope, and images were prepared with Fluoview version 4.3 software (Olympus Corporation). Quantitation of analytes or antigens was conducted by counting events per high-powered field, minimum four fields per ventricle or splenic section, using at least triplicate animals per treatment. For high-resolution micrographs, slides were imaged on a Zeiss ELYRA LSM 880 microscope using a \times 20 planar apochromat objective with AiryScan function. Images were acquired and processed using Zeiss ZEN 2.3 software (Carl Zeiss) and Imaris Viewer (version 9.8.0, Oxford Instruments) (for z-stack deconvolution).

Protein extracts from fresh-frozen tissue

Border regions of post-MI left ventricular tissue and spleens were excised at predetermined timepoints after the experimental procedure and washed in cold PBS. After being patted dry on a sterile filter paper and then weighed, tissues were placed in 2.0-ml screwcap cryovials and immersed in liquid nitrogen for storage at -80 °C. For protein isolation, tissues were thawed on ice in cold lysis buffer, finely minced with scissors and then disrupted using a glass homogenizer. Suspensions were incubated on ice for 1 hour with occasional vortexing and then sonicated twice for 10-second intervals. Supernatants were clarified by centrifugation at 12,000g at 4 °C for 10 minutes and transferred to new sample tubes for use in immunoblotting. Prior to electrophoresis, protein quantities were determined by Bradford assay.

Nuclear extracts

Halved spleens (approximately 35–40 mg), either freshly isolated or frozen, were incubated in 1.5-ml Eppendorf tubes on ice in cold PBS followed by PBS diluted 1:5 in distilled deionized water. Tissue was minced into small pieces with scissors and spun at 500g, and PBS solution was replaced with hypotonic lysis buffer (10 mM HEPES (pH 7.5), 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 1 \times concentrate cOmplete protease inhibitor cocktail and 50 mM sodium orthovanadate). Tissue was further minced, vortexed gently and incubated for 10 minutes on ice, followed by addition of 0.5% Triton X-100. Cell suspensions were spun at 1,500g; supernatants ('cytoplasmic' fraction) were transferred to collection tubes; and pellets were resuspended in nuclear extraction buffer (20 mM HEPES (pH 7.5), 20 mM KCl, 80 mM NaCl, 25% (v/v) glycerol, 0.5 mM EDTA, 1 mM DTT, 1 \times concentrate cOmplete protease inhibitor cocktail and 50 mM sodium orthovanadate) for 30 minutes on ice. Suspensions were intermittently vortexed and finally centrifuged

at 12,000g (4 °C) for 15 minutes. Supernatants were collected, and both cytoplasmic and nuclear extracts were stored at –80 °C for use in immunoblotting. Prior to electrophoresis, sample protein concentration was measured by Bradford assay.

Immunoprecipitation and immunoblotting

Immunoprecipitation. 300 µg of cell extracts was incubated in lysis buffer and 2 µg ml⁻¹ mouse monoclonal anti-TRAF3 (Santa Cruz Biotechnology), rabbit polyclonal anti-TRAF6 (Cell Signaling Technology) or mouse monoclonal anti-RIPK1 (BD Biosciences) antibodies, respectively. Samples were rotated continuously at 4 °C overnight and subsequently incubated with 0.10 volumes of Protein G-conjugated Dynabeads (Thermo Fisher Scientific) at 4 °C for an additional 90 minutes. Antigen-antibody complexes were immobilized using a DynaSpin column (Thermo Fisher Scientific), and the unbound fraction was saved for immunoblot analysis. Beads were subsequently washed in lysis buffer and PBS, sequentially, and antigen-antibody complexes were eluted using 4× Laemmli sample loading buffer and heating at 95 °C for 5 minutes. Samples were loaded onto 8% SDS-PAGE gels, and isolated proteins were subsequently probed by immunoblotting for proteins as indicated. Ubiquitin pull-downs were performed using a Pierce Ubiquitin Enrichment Kit (Thermo Fisher Scientific) according to the manufacturer's protocol, and eluted proteins were stored at –80 °C prior to immunoblotting.

Immunoblotting. Protein lysates collected as described were loaded as 10-µg aliquots onto 6% or 12% SDS-PAGE gels. Separated proteins were transferred onto polyvinylidene difluoride (PVDF) membranes and immunoblotted with primary antibodies as indicated (listed in Supplementary Table 6). HRP-conjugated secondary antibodies (1:25,000 dilution; Bio-Rad) were incubated with blots, and labeled antibody-antigen complexes were developed using West Pico PLUS ECL reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. Blots were exposed and images collected on a Bio-Rad ChemiDoc XRS+ imaging system, and analysis was conducted using Image Lab version 6 software.

RNA isolation and real-time qPCR

Frozen peri-infarct region left ventricular tissue or spleen (approximately 40–60 mg) was digested in 800 µl of TRIzol solution (Thermo Fisher Scientific), followed by standard chloroform separation and 75% ethanol RNA precipitation. RNA concentrations were determined with a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific), and 1 µg of RNA was reverse transcribed to cDNA using All-In-One 5× RT PCR Master Mix (Applied Biological Materials) according to the manufacturer's protocol. Sample cDNA was then diluted 1:10 and used for qPCR gene expression analysis using BrightGreen 2× qPCR Master Mix (Applied Biological Materials), with 10 mM target-selective primers as listed in Supplementary Table 7. PCR reactions were performed using the following cycling conditions: 95 °C for 15 seconds, 60 °C for 15 seconds and 72 °C for 15 seconds over a 40-cycle reaction sequence on a Roche Light-Cycler 96 instrument. Quantitation of transcript was performed using the $\Delta\Delta C_t$ method, using HPRT or β -actin (indicated in the figure legends) as reference (control) PCR products. For most experiments, $\Delta\Delta C_t$ values (the effect of MI on the target gene of interest) were compared between WT and *Clap2*^{-/-} mice, and a relative expression ratio was calculated with WT MI expression change being assigned a reference value of 1.

ELISA

For clinical serum or lysate samples, proteins were isolated as described above and were used for measurement by human cIAP1 or cIAP2 ELISA (MilliporeSigma, RAB1369 and RAB0027). Assays were conducted as recommended according to the manufacturer's protocols. Intracellular-isolated cIAP measurements (from PBMC lysates) were normalized by standard Bradford protein assay. For mouse analyses,

spleen cells were cultured at densities of 1 × 10⁶ cells per milliliter in RPMI/5% FBS for 48 hours, and conditioned media were collected and stored at –80 °C for use in ELISA. Conditioned media from splenocyte cultures were collected 48 hours after cell plating of 1 × 10⁶ cells per well (12-mm wells) and subsequently used for detection of IL-10 or IL-23 using DuoSet ELISA kits (IL-10: DY417; IL-23: DY1887 (R&D Systems/Bio-Techne)) according to the manufacturer's protocols.

Statistical analysis

Sample size calculations were performed for mouse MI experiments based upon estimation of effect sizes from preliminary experiments. In general, observation of relative performance (that is, magnitude of biological effect size) was compared among WT, *Clap2*^{-/-} or *Clap1*^{-/-} mice. Results were applied to subsequent experiments, with sample sizes determined according to methods summarized in ref. 81 using calculation formulas suitable for continuous variable measurements. A single exception was the use of linear regression statistical testing for survival analysis in Fig. 5d, where subject animal differences were evaluated ad hoc during experiments for cardiac injury measurements. Statistical calculations for experimental outputs were made from individual raw data using GraphPad Prism version 8 or version 9 software (GraphPad Software); sample sizes and selection of statistical tests are indicated in the figure legends.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data supporting the findings in this study are included in the main article and associated files. Source data are provided in the Supplementary Information attachment accompanying the paper. Source data from gene set enrichment analysis and gene expression analyses were tabulated and are available in Supplementary Tables 2 and 3.

References

- Martin, S. S. et al. 2024 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association. *Circulation* **149**, e347–e913 (2024).
- Wellings, J., Kostis, J. B., Sargsyan, D., Cabrera, J. & Kostis, W. J. Risk factors and trends in incidence of heart failure following acute myocardial infarction. *Am. J. Cardiol.* **122**, 1–5 (2018).
- Frangogiannis, N. G. Regulation of the inflammatory response in cardiac repair. *Circ. Res.* **110**, 159–173 (2012).
- Andreadou, I. et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. *Cardiovasc. Res.* **115**, 1117–1130 (2019).
- Swirski, F. K. & Nahrendorf, M. Cardioimmunology: the immune system in cardiac homeostasis and disease. *Nat. Rev. Immunol.* **18**, 733–744 (2018).
- Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N. Engl. J. Med.* **377**, 1119–1131 (2017).
- Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. *J. Am. Coll. Cardiol.* **77**, 1845–1855 (2021).
- Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N. Engl. J. Med.* **381**, 2497–2505 (2019).
- Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in cardiac injury and repair. *Nat. Rev. Immunol.* **15**, 117–129 (2015).
- Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. *Cold Spring Harb. Perspect. Biol.* **4**, a006049 (2012).
- Jaén, R. I. et al. Innate immune receptors, key actors in cardiovascular diseases. *JACC Basic Transl. Sci.* **5**, 735–749 (2020).

12. Sun, M. et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. *Circulation* **110**, 3221–3228 (2004).
13. Maekawa, Y. et al. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling. *Circulation* **120**, 1401–1414 (2009).
14. Fallach, R. et al. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. *J. Mol. Cell. Cardiol.* **48**, 1236–1244 (2010).
15. Harpster, M. H. et al. Earliest changes in the left ventricular transcriptome post-myocardial infarction. *Mamm. Genome* **17**, 701–715 (2006).
16. Lalaoui, N. & Vaux, D. L. Recent advances in understanding inhibitor of apoptosis proteins. *F1000Res.* **7**, F1000 Faculty Rev-1889 (2018).
17. Silke, J. & Meier, P. Inhibitor of apoptosis (IAP) proteins—modulators of cell death and inflammation. *Cold Spring Harb. Perspect. Biol.* **5**, a008730 (2013).
18. Jensen, S., Seidelin, J. B., LaCasse, E. C. & Nielsen, O. H. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. *Sci. Signal.* **13**, eaax8295 (2020).
19. Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M. & Goeddel, D. V. The TNFR2–TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* **83**, 1243–1252 (1995).
20. Peltzer, N., Darding, M. & Walczak, H. Holding RIPK1 on the ubiquitin leash in TNFR1 signaling. *Trends Cell Biol.* **26**, 445–461 (2016).
21. Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF- κ B and MAPK activation by members of the TNF family of receptors. *Sci. Signal.* **5**, ra22 (2012).
22. Zarnegar, B. J. et al. Noncanonical NF- κ B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. *Nat. Immunol.* **9**, 1371–1378 (2008).
23. Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF- κ B signaling. *Nat. Immunol.* **9**, 1364–1370 (2008).
24. Tseng, P.-H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nat. Immunol.* **11**, 70–75 (2010).
25. Zhong, B. et al. Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. *Science Signaling* **6**, ra35 (2013).
26. Hunter, A. M., LaCasse, E. C. & Korneluk, R. G. The inhibitors of apoptosis (IAPs) as cancer targets. *Apoptosis* **12**, 1543–1568 (2007).
27. Conte, D. et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. *Mol. Cell. Biol.* **26**, 699–708 (2006).
28. Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c–dependent caspase activation by eliminating IAP inhibition. *Cell* **102**, 33–42 (2000).
29. Beug, S. T. et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. *Nat. Biotechnol.* **32**, 182–190 (2014).
30. Chesi, M. et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nat. Med.* **22**, 1411–1420 (2016).
31. Yang, C. et al. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. *J. Exp. Clin. Cancer Res.* **35**, 158 (2016).
32. Pemmaraju, N. et al. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. *Blood Adv.* **5**, 3163–3173 (2021).
33. Conze, D. B. et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. *Mol. Cell. Biol.* **25**, 3348–3356 (2005).
34. Yan, X. et al. Deleterious effect of the IL-23/IL-17A axis and $\gamma\delta$ T cells on left ventricular remodeling after myocardial infarction. *J. Am. Heart Assoc.* **1**, e004408 (2012).
35. Ismahil, M. A. et al. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure. *Circ. Res.* **114**, 266–282 (2014).
36. Leuschner, F. et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopenia. *J. Exp. Med.* **209**, 123–137 (2012).
37. de Almagro, M. C., Goncharov, T., Newton, K. & Vucic, D. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. *Cell Death Dis.* **6**, e1800 (2015).
38. McComb, S. et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. *Cell Death Differ.* **19**, 1791–1801 (2012).
39. Yamashita, M. & Passegué, E. TNF- α coordinates hematopoietic stem cell survival and myeloid regeneration. *Cell Stem Cell* **25**, 357–372 (2019).
40. Clarke, N., Jimenez-Lara, A. M., Voltz, E. & Gronemeyer, H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. *EMBO J.* **23**, 3051–3060 (2004).
41. Infante, J. R. et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. *J. Clin. Oncol.* **32**, 3103–3110 (2014).
42. Nauta, S. T., Deckers, J. W., van Domburg, R. T. & Akkerhuis, K. M. Sex-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008. *Circulation* **126**, 2184–2189 (2012).
43. Ketchum, E. S. et al. The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. *Eur. Heart J. Acute Cardiovasc. Care* **3**, 46–55 (2014).
44. Peters, S. A. E. et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. *Circulation* **143**, 650–660 (2021).
45. Ye, Q., Zhang, J. & Ma, L. Predictors of all-cause 1-year mortality in myocardial infarction patients. *Medicine* **99**, e21288 (2020).
46. Sulo, G. et al. Trends in the risk of early and late-onset heart failure as an adverse outcome of acute myocardial infarction: a Cardiovascular Disease in Norway project. *Eur. J. Prev. Cardiol.* **24**, 971–980 (2017).
47. Pocock, S. et al. Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis. *Open Heart* **8**, e001499 (2021).
48. Massa, M. et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. *Blood* **105**, 199–206 (2005).
49. van der Laan, A. M. et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. *Am. Heart J.* **163**, 57–65 (2012).
50. Zeng, S. et al. Trajectories of circulating monocyte subsets after ST-elevation myocardial infarction during hospitalization: latent class growth modeling for high-risk patient identification. *J. Cardiovasc. Trans. Res.* **11**, 22–32 (2018).
51. Chia, S. et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. *Am. J. Cardiol.* **103**, 333–337 (2009).

52. Bertrand, M. J. M. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. *Immunity* **30**, 789–801 (2009).
53. Mahoney, D. J. et al. Both cIAP1 and cIAP2 regulate TNF α -mediated NF- κ B activation. *Proc. Natl Acad. Sci. USA* **105**, 11778–11783 (2008).
54. Fulda, S. Promises and challenges of Smac mimetics as cancer therapeutics. *Clin. Cancer Res.* **21**, 5030–5036 (2015).
55. Dutta, P. et al. Myocardial infarction activates CCR2⁺ hematopoietic stem and progenitor cells. *Cell Stem Cell* **16**, 477–487 (2015).
56. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. *Science* **325**, 612–616 (2009).
57. Dutta, P. et al. Myocardial infarction accelerates atherosclerosis. *Nature* **487**, 325–329 (2012).
58. Wong, W. W.-L. et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. *Blood* **123**, 2562–2572 (2014).
59. Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* **3**, 673–682 (1995).
60. Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S. & El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. *Cancer Res.* **59**, 2770–2775 (1999).
61. Niessner, A. et al. Prognostic value of apoptosis markers in advanced heart failure patients. *Eur. Heart J.* **30**, 789–796 (2009).
62. Secchiero, P. et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. *PLoS ONE* **4**, e4442 (2009).
63. Skau, E. et al. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. *Eur. J. Prev. Cardiol.* **24**, 1576–1583 (2017).
64. Wang, X. et al. Blocking the TRAIL-DR5 pathway reduces cardiac ischemia-reperfusion injury by decreasing neutrophil infiltration and neutrophil extracellular traps formation. *Cardiovasc. Drugs Ther.* **39**, 983–999 (2024).
65. Tanner, M. A., Dougherty, K. & Grisanti, L. A. Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction. *J. Pharmacol. Exp. Ther.* **392**, 103600 (2025).
66. Benedict, C. A. & Ware, C. F. TRAIL: not just for tumors anymore? *J. Exp. Med.* **209**, 1903–1906 (2012).
67. Hematianlarki, M. & Nimmerjahn, F. Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies. *Immunol. Rev.* **328**, 372–386 (2024).
68. Chai, J. et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* **406**, 855–862 (2000).
69. Bai, L., Smith, D. C. & Wang, S. Small-molecule SMAC mimetics as new cancer therapeutics. *Pharmacol. Ther.* **144**, 82–95 (2014).
70. Yang, Q.-H. & Du, C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and Livin in HeLa cells. *J. Biol. Chem.* **279**, 16963–16970 (2004).
71. Creagh, E. M., Murphy, B. M., Duriez, P. J., Duckett, C. S. & Martin, S. J. Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. *J. Biol. Chem.* **279**, 26906–26914 (2004).
72. Darding, M. et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. *Cell Death Differ.* **18**, 1376–1386 (2011).
73. Rodrigue-Gervais, I. G. et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. *Cell Host Microbe* **15**, 23–35 (2014).
74. Annibaldi, A. et al. Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. *Mol. Cell* **69**, 566–580 (2018).
75. Biswas, D. D. et al. Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis. *J. Neuroinflammation* **19**, 158 (2022).
76. Seidelin, J. B. et al. IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn's disease. *Clin. Exp. Immunol.* **215**, 291–301 (2024).
77. Li, S., Yang, P., Xu, L. & Li, M. Blocking of Birc3/TLR4/Myd88 signaling protects carbapenem-resistant *klebsiella pneumoniae* in a mouse model of infection. *Transplant. Immunol.* **69**, 101464 (2021).
78. Zhang, L. et al. Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure. *Nat. Cardiovasc. Res.* **1**, 1195–1214 (2022).
79. Amaral, M. L., Erikson, G. A. & Shokhirev, M. N. BART: bioinformatics array research tool. *BMC Bioinformatics* **19**, 296 (2018).
80. Chen, Y.-L. et al. A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. *J. Exp. Med.* **210**, 2515–2522 (2013).
81. Dell, R. B., Holleran, S. & Ramakrishnan, R. Sample size determination. *ILAR J.* **43**, 207–213 (2002).

Acknowledgements

This work was funded by the Canada First Research Excellence Fund for the Brain-Heart Interconnectome (CFREF-2022-00007); the Government of Canada through Genome Canada and Ontario Genomics (OGI-2050); and the Brain Canada Foundation and the Heart and Stroke Foundation of Canada for Heart-Brain Connection IMPACT Award to P.P.L. R.G.K. is a recipient of funding support from the Canadian Institutes of Health Research. D.S. was a recipient of a Heart and Stroke Foundation of Canada research fellowship.

Author contributions

D.S. developed the study concept, planned and performed experiments, analyzed data and wrote and edited the paper. L.Z. and M.A.-K. performed experiments, analyzed data and edited the paper. S.R., M.G., F.D., B.M., Q.D., C.B. and X.Z. performed experiments. R.S. planned experiments, performed surgeries, analyzed data and edited the paper. R.J. and S.P. recruited and collected clinical patient samples and analyzed data. M.O. planned experiments and edited the paper. S.T.B. and E.C.L. planned experiments, analyzed data and edited the paper. K.J.R. planned experiments, analyzed data and edited the paper. T.W.M. provided experimental resources and edited the paper. B.H. coordinated clinical recruitment, analyzed data and edited the paper. R.G.K. provided experimental resources, analyzed data and edited the paper. P.P.L. is the principal investigator, developed the study concept, coordinated clinical recruitment, analyzed data and wrote and edited the paper.

Competing interests

E.C.L. is a co-founder and the Chief Scientific Officer of Protaxis Therapeutics, Inc. All other authors report no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s44161-026-00782-x>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s44161-026-00782-x>.

Correspondence and requests for materials should be addressed to Peter P. Liu.

Peer review information *Nature Cardiovascular Research* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.


Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,

as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2026



Extended Data Fig. 1 | See next page for caption.


Extended Data Fig. 1 | Upregulation of cIAP2 post-MI. **a** and **b**) Gene expression changes within infarcted left ventricle ('infarct') are marked at 24- and 48-hours post-MI, as assessed by hierarchical clustering and principal component analyses of the open-source GEO dataset GSE4648. Analyses carried out using Geo2R and the open-source BART bioinformatics tool. **c**) Differential gene expression patterns identified in 24-hour post-MI ventricle compared with sham control. cIAP2 (Birc3) is significantly upregulated. **d**) LV infarct region gene expression timecourse of cIAP2 (maroon) and related transcripts cIAP1 (blue) and Xiap (green), contrasted with measured cardiac marker *tnnt2* (Cardiac Troponin T) and inflammatory marker *cxcl1*. **e**) Compiled expression timecourse of representative myeloid-related transcripts (maroon) and lymphoid transcripts

(blue) from LV infarct region post-MI. *ptprc* (black) = hematopoietic marker gene transcript. **f**) Gene Ontology (GO) pathway enrichment following MI identifies multiple networks requiring cIAP2. **g**) *NOD1*^{-/-} mice have reduced systolic dysfunction and cardiac inflammation following MI relative to WT control mice. Control-operated mice: N = 3; MI-operated mice: N = 5. Ejection fraction: N = 4 MI-operated per group. **h**) cIAP2 is expressed at lower levels, along with inflammatory genes *RIPK1*, *IRAK4* and *TRAF6*, in multiple danger signaling receptor-deficient mouse models following MI. Image is representative of two similar experiments. Error bars denote Mean \pm SD; p values were calculated using one-way ANOVA with Bonferroni's correction (**g**, upper panel) or two-sided t-test (**g**, lower panel).




Extended Data Fig. 2 | cIAP2 deficiency reduces post-MI injury. **a** Left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) measurements presented as % change from baseline (pre-MI) echocardiography in 28-day MI-operated mice. Right panel shows absolute LVESD measurements including Control operated mice, noting differences in systolic dimension of control animals. **b** Immunoblot of apoptotic proteins Annexin A1, cleaved Poly-adenosine diphosphate (PARP) and cleaved Caspase 8 from Day 3 post-MI left ventricle tissue lysates. β -actin was used as an expression control. **c** Quantitative PCR measuring expression of representative injury-associated genes Brain-Natriuretic Peptide (*Nppb*), Myosin Heavy chain

Isoform 7 (*Myh7*), Tumour Necrosis Factor- α (*Tnfa*) and Transforming Growth Factor- β (*Tgfb1*) 28 days post-MI. $N = 4$ per treatment, target genes were normalized to expression of β -actin. **d** Immunoblot of cardiac HMGB1 and TGF β 1 from Day 28 post-MI left ventricle tissue lysates. Vinculin was used as an expression control. Imaging representative of three similar experiments. **e** Flow cytometry gating strategy for cell quantitation in Figs. 2b and 3b). Error bars denote Mean \pm SD; p values were calculated using two-way ANOVA with Bonferroni's correction (a right panel), one-way ANOVA using Bonferroni's correction (a left and centre panels), two-sided t-tests (c).

**Extended Data Fig. 3 | Immune-derived cIAP2 drives inflammation post-MI.**


a) Bone marrow chimeric recipient heart and lung weights 28 days post-MI. Controls: N = 5 (WT)/3 (*ciap2*^{-/-}); MI-operated: N = 17 per group. Results represent aggregate data from three experiments. **b**) Capillary density (green) of MI infarct border region. Scale bar = 50 μ m. N = 4 per group, mean of 3 representative fields per animal. **c**) Flow cytometric quantitation of heart-infiltrating neutrophils and Ly6C^{hi} monocytes from bone marrow transplanted mice Day 28 post-MI. Control: N = 3; WT chimeric MI: N = 4; *ciap2*^{-/-} chimeric MI: N = 4. **d**) Inflammatory cytokine production from splenocytes isolated from bone marrow chimeric mice 28 days post-MI. N = 6 splenocyte cultures/treatment group. **e**) Left

panel: flow cytometric quantitation of lymphocyte populations (CD4 + T cells, CD8 + T cells, B cells) from left ventricle tissue Day 28 post-MI. Right panels: Immunofluorescence microscopy assessing Th17 cell presence (white arrowheads) in left ventricular MI border zone. Green – IL-17A; red – CD3 ζ chain; blue – DAPI. 400x magnification; scale bar denotes 50 μ m. Cell quantitation was performed in WT: N = 3, *ciap2*^{-/-}: N = 4, 4 fields counted per animal. Error bars denote Mean \pm SD; p values were calculated using two-way ANOVA with Bonferroni's correction (a), one-way ANOVA with Bonferroni's correction (b, c) or two sided t-test (d, e).




Extended Data Fig. 4 | cIAP2^{-/-} reverse chimeric mice exhibit greater post-MI injury. **a)** Heart and lung weights normalized to tibia length from reverse bone marrow transplanted mice. **b)** LVESD measurements of reverse bone marrow chimeric mice. **a)-b):** Controls: N = 4; WT recipient MI: N = 8; cIAP2^{-/-} recipient MI: N = 7. **c)** Estimation of capillary density by Isolectin B4 staining (green); nuclei (DAPI) – blue; scale bar = 50 μ m. N = 4 per treatment. Data presented are

aggregates from two experiments. **d)** and **e)** Flow cytometry and cell quantitation from reverse bone marrow chimeric mice 28 days post-MI. Control operated mice: N = 3; MI-operated mice: N = 5 per group. Data presented are aggregates from two experiments. Error bars denote Mean \pm SD; p values were calculated using one-way ANOVA with Bonferroni's correction.



Extended Data Fig. 5 | Altered myeloid immune cell dynamics in *cIAP2*^{-/-} mice. **a)** (upper panel) *cIAP2* upregulation was observed in patient blood leukocyte lysates from MI-sufferers, and not from control or non-MI, heart failure-diagnosed patients. (lower panel) Murine circulating leukocytes demonstrated increased *cIAP2* protein expression Day 7 post-MI. **b)** Quantitation of leukocyte intracellular *cIAP1* and *cIAP2* protein expression from stable coronary artery disease (CAD) or MI patients using respective enzyme-specific immunoassay (ELISA). Outputs were normalized to whole protein ($\mu\text{g}/\text{ml}$) of cell lysate. $N = 6$ representative samples per group. **c)** Representative gating of peripheral blood myeloid (CD11b^+) cells Day 3 post-MI. Representative gating **d)**


and quantitation **e)** of peripheral blood B and T lymphocytes (B cells, CD4^+ T cells, CD8^+ T cells) from Day 3 post-MI WT and *cIAP2*^{-/-} mice. **f)** Measurement of splenic lymphocytes collected 3- and 7- days post-MI. **g)** Measurement of LV infiltrating lymphocytes collected 7 days post-MI. **h)** Schematic diagram summarizing cardiac injury inducing leukocyte production and mobilization from the bone marrow and spleen, with subsequent infiltration into the heart being suppressed in the setting of *cIAP2* deficiency. Error bars denote Mean \pm SD; p values were calculated using two-sided t-test (**a**) or one-way ANOVA followed by Bonferroni's correction (**c**, **d**).



Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | cIAP2 promotes MI-stimulated inflammatory cell signaling. **a**) cIAP2 expression coincides with TRAF3 loss in splenocytes following MI. Data are representative of two separate experiments. **b**) Representative immunoblotting from mouse splenocyte homogenates 48 h post-MI showing expression changes of IAP proteins and TRAF3 in WT, cIAP2^{-/-} or cIAP1^{-/-} mice. **c**) Spleen expression of pro-inflammatory signal transduction intermediates from WT or cIAP2^{-/-} mice 7 days post-MI. Immunoblot representative of three similar experiments. **d**) cIAP2 co-immunoprecipitation with TRAF3, an identified substrate for cIAP2 E3 ligase activity, from splenocytes Day 3 post-MI. Immunoblots are representative of three experiments, quantitation by densitometry relative to TRAF3. **e**) cIAP2 promotes TRAF3 (upper panel) K48 polyubiquitination (26S proteasomal targeting signal) and RIPK1 (lower panel) K63 polyubiquitination (activation/anti-apoptotic signal) in 24-hour MI-conditioned splenocytes. Blots of input protein lysate show


TRAF3, RIPK1 cIAP1/2 expression as well as changes to non-canonical NF- κ B pathway factors (NF- κ B-inducible kinase, I κ B kinase- α , NF- κ B2 (p100/52) and RelB). Representative of four experiments. **f**) Reduced nuclear translocation of NF- κ B components RelA (p65) and NF- κ B1 (p50) in cIAP2-deficient splenocytes isolated following MI. Lamin B is a nuclear antigen control. N = 3 per treatment group; image is representative of two similar experiments. **g**) Expression of inflammatory genes *Tnfa*, *Il1b* and *Il6* from WT and cIAP2^{-/-} splenocytes at Day 3 post-MI (N = 3/group). Values presented as expression normalized to respective strain sham controls. **h**) Schematic diagram depicting proposed role for cIAP2 following MI. Danger signal engagement drives cIAP2-mediated regulation of pro-inflammatory signaling, promoting NF- κ B activity and promoting degradation of regulator TRAF3. Error bars denote Mean \pm SD; p values were calculated using two-sided t test (**g**).



Extended Data Fig. 7 | See next page for caption.

Extended Data Fig. 7 | TRAIL is upregulated by cIAP2^{-/-} mice post-MI. **a**) mRNA expression of *Tnfa*, *Il1b*, and *Il6* normalized to HPRT from Day 7 post-MI WT or cIAP2^{-/-} spleens. N = 3 per treatment group. **b**) Immunoblotting of splenocyte lysates from 7-day post-MI from WT or cIAP2^{-/-} mice were immunoblotted for TRAIL (top) and TNF α , cleaved (active) Caspase 8 (p41 and p18), cleaved Caspase 3 (p17/19), Annexin A1 or vinculin. Imaging representative of two similar experiments, respectively. **c**) (Top panel) TRAIL and IRF1 protein expression from bone marrow cells collected from WT and cIAP2^{-/-} mice 24-hours post-MI. (Bottom panel) Expression of TRAIL compared between dendritic cells (CD11c⁺) isolated from WT, cIAP2^{-/-} and cIAP1^{-/-} bone marrow 24-hours post-MI. **d**) High-resolution immunofluorescence microscopy of spleen sections detecting TRAIL and DR5 in cIAP2^{-/-} mice 3 days post-MI; arrowheads indicate increased colocalized staining of TRAIL on cell surface of BST2⁺ splenocytes. Scale bar = 25 μ m; images representative of three animals per treatment. **e**) Increased LVESD 28 days post-MI in both WT and cIAP2^{-/-} MI recipient mice after

anti-TRAIL (N2B2) antibody treatments. Control IgG2 recipients: N = 3 sham operated controls (WT); N = 4 WT and cIAP2^{-/-} mice per MI treatment group. Anti-TRAIL recipients: N = 3 sham operated controls (WT); N = 5 WT and cIAP2^{-/-} mice per MI treatment group. **f**) Flow cytometry of inflammatory cells from hearts (left panels) and spleens (right panels) of MI recipient mice following TRAIL neutralizing antibody treatment. cIAP2^{-/-} mice exhibit more pronounced increases in cardiac tissues. Control IgG2 recipients: N = 3 sham operated controls (WT); N = 4 WT and cIAP2^{-/-} mice per MI treatment group. Anti-TRAIL recipients: N = 3 sham operated controls (WT); N = 5 WT and cIAP2^{-/-} mice per MI treatment group. **g**) Schematic summary of proposed activity of splenic cIAP2^{-/-} pDCs following TNF α or death-promoter TNFSF ligand (TRAIL) signaling (via TNFR1 or DR5, respectively). Error bars denote Mean \pm SD; p values were calculated using two-sided t test (**a**), two-way ANOVA with Tukey's test (**e**) or two-way ANOVA with Bonferroni's correction (**f**).



Extended Data Fig. 8 | See next page for caption.

Extended Data Fig. 8 | LCL161 treatment reduces MI injury. **a)** *in vivo* dose titration of LCL161. Peripheral blood cells were isolated 48 h following stimulation of mice with isoproterenol (10 mg/kg) and gavage of vehicle control or 2, 10 or 25 mg/kg of LCL161. Data shown is of representative 2 vehicle control-gavaged mice (top) or 10 mg/kg-gavaged LCL161 (bottom). **b)** Expression of inflammatory signal transduction intermediates by *ex vivo*-differentiated bone marrow-derived dendritic cells. Cell lysates were collected following 48-hour stimulation as indicated in presence or absence of LCL161. Immunoblot is representative of 2 similar experiments. **c)** flow cytometry gating for cell quantitation of monocytes or neutrophils from hearts of MI-treated C57Bl/6 mice receiving either vehicle (top) or LCL161 (10 mg/kg; bottom). Dotplot is representative of 5 mice per treatment. **d)** intracellular flow cytometry measuring cardiac Th17 cells from mice treated as in c). Controls: N = 2; MI-operated: N = 3 per group. **e)** LCL161-treated cIAP1^{-/-}, but not cIAP2^{-/-}, mice

demonstrate improvement in ejection fraction, remodeling and heart weight improvement following MI. WT: MI + Vehicle: N = 5, MI + LCL: N = 5; cIAP1^{-/-}: MI + Vehicle: N = 6, MI + LCL: N = 6; cIAP2^{-/-}: MI + Vehicle: N = 8, MI + LCL: N = 7. Data are presented as aggregates from two representative experiments. **f)** reduced inflammatory cell infiltrate in hearts of cIAP1^{-/-} mice treated with LCL161. Controls: N = 2; MI-operated: N = 4 vehicle treated; N = 5 LCL treated. **g)** Quantitative PCR of heart tissue isolates at 28 days post-MI for measurement of injury/inflammation gene transcription. N = 4/group for each target gene. **h)** Quantitation of spleen and bone marrow myeloid (CD11b⁺) cells Day 28 post-MI. Controls: N = 2/mouse strain; MI: N = 4/mouse strain. Error bars denote Mean +/- SD; p values were calculated using one-way ANOVA with Bonferroni's correction (**d, f**) two-way ANOVA with Bonferroni's correction (**e**) or two-sided t test (**g**).

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Flow cytometry: FACSdiva V8.2 (Becton-Dickinson); Tissue morphometry: Image J (NIH Open access); Immunofluorescence microscopy: Fluoview (Olympus); Human plasma proteomics: SomaScan (Agilent-SomaLogic); Echocardiography: VevoSonix 3.1.1 or 3.0-770 (Fujifilm/Visualsonic); Histochemistry: ImageScope (Leica); Immunoblotting: Image Lab V6.0 (Bio-Rad)
Data analysis	Cytometry: FACSdiva V8.2 (BD) and FlowJo V10.8 (Treestar); Histology and tissue morphometry: Image J (NIH); Immunofluorescence microscopy: Fluoview V4.3 (Olympus), ZENBlue V2.3 (Zeiss), Imaris Viewer V9.8 (Oxford Instruments); Immunoblotting: Image Lab V6.0 (Bio-Rad); Transcriptional analysis: Murine GSEA - Bioinformatics Array Research Tool (BART - Amaral Lab, Salk Institute) (bart.salk.edu); Quantitation and Statistical analysis: Excel 2010 (Microsoft) and GraphPad/Prism V9.2 (GraphPad Software Inc.)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Transcriptional expression data from murine heart (Extended Data Figure 1) was collected from the NCBI Geo DataSet GSE4648 (ncbi.nlm.nih.gov/gds/?term=2329); raw data was used for presented graphics and images located in Main Figures 1-4 as well as Extended Data Figures 1-8. More raw data from GSE4648 analysis is located in Supplemental Table 3. No unique data codesets were generated for these studies. Authors are available for contact regarding any specific data requests.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

Acute presentation of ischemic cardiomyopathy, in particular myocardial infarction, is strongly skewed to male patients. Data collection from our three patient sample repositories reflects this consistently, and as we have presented a smaller number of randomly-selected patients we did not perform sex-based experimental analysis and we did not disaggregate the patient data. We have disclosed the number of male and female patients within the study cohorts. All patient and healthy control samples were collected once donors provided informed, written consent.

Population characteristics

Patient characteristics are summarized in Supplemental Table 2. SomaScan analysis of acute HF patients was conducted in a ratio of 3:4 ischemic: non-ischemic HF, and distribution of males and females was 1:2 and 2:2, respectively. Immunoblotting assay of ischemic MI vs non-MI patients (HF Cause cohort) used samples from males only. Serum, PBMC and leukocyte lysate samples for MI vs CAD analyses were conducted with similar sex and health indicator distributions, where male:female ratios were consistent (7:2 MI vs 9:4 CAD) and key indicators such as hypertension, smoking history or diabetic status were similar between patient groups.

Recruitment

The HF-CAUSE study (Evaluation of Existing Biomarker Candidates to Accurately Classify the Etiology of Heart Failure) recruited patients who were diagnosed with heart failure (any type) within the past 2 years (HFpEF within 5 years). Plasma samples were collected for leukocytes and serum. Patient demographics including past medical history, family history of cardiovascular disease, history of smoking and alcohol use, current medications, BP and HR are listed in Supplemental Table 3. We also collected all diagnostic reports that led to the diagnosis of heart failure. Patients are followed by chart review at 30 days and 6 months after enrollment. Patients recruited at UOHI will be followed by chart review for life. A total of 435 patients were recruited by 5 Ontario, Canada sites.

Serial Biomarker study (Time Related Changes in Biomarkers; a Sub-study for Evaluation of existing Biomarker Candidates to Accurately Classify the etiology of heart failure) is a sub-study of HF-CAUSE. The subgroup of patients were enrolled if newly diagnosed with heart failure (within 3 months) and currently admitted to hospital with acute decompensated heart failure. Blood samples were collected in hospital upon admission and between 3-30 days of admission and prior to discharge.

PCI for MI or CAD study (general blood collection protocol) was created to catalog serum samples for characterizing patient cellular and soluble biomarkers of injury. Patients provided blood samples following admission. MI sufferers presenting for PCI are predominantly male as was reflected in the patient demographics recorded in Supplemental Table 2.

Ethics oversight

Human research is conducted with approval under the guidelines of the Ottawa Health Science Network Research Ethics Board where patients have provided informed consent. The studies operate in compliance with OHSN-REB Protocols #20140869, #20150428, and #20160516-01H respectively.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

used Appropriate sample sizes were calculated for experiments based upon preliminary determination of biological effect size. Physiological (e.g. echocardiography), pathological (e.g. normalized heart weight: tibia length) investigations used a minimum of N=5 for MI treatment, N=3

minimum for sham operated control mice. Flow cytometric measurements and molecular/biochemical studies employed smaller groups (N=3 minimum per treatment per group), with individual studies replicated at least twice and experimental data were presented in aggregate groups. Specific sample sizes and experimental replication is listed in the Figure Legends. Experimental procedure (MI surgery) elicits a small proportion of acute, procedure-related mortality (i.e. pneumothorax, uncontrolled bleeding, isoflurane hypersensitivity) which was also considered in study design.

Data exclusions	Data were not excluded from study reporting. Animals who suffered perioperative (same day) death were not included in study reporting.
Replication	Experimental data were generated by a minimum of two independent, consistently-executed experiments where reproducible results were obtained. For whole animal measurements (heart/lung weight, internal ventricular dimension, ejection fraction) data from identified treatment groups are presented as aggregate of replicated experiments.
Randomization	Animals within groups (knockout vs wildtype, chimaeric background or Smac mimetic treatment) were randomized to treatment prior to study (MI or sham operation and experimental end timepoint), except for replication experiments of short term responses (fixed timepoint studies). Animals were not randomized within the same experiment by sex, but experiments in males and females were conducted in parallel from same origin litters (for 28 day MI studies) whenever adequate animal numbers allowed. Experiments were conducted with identical designs and groups were randomized to treatment.
Blinding	Surgeon, imaging (echocardiography and microscopy) and pathology measurement were blinded. Data analysis was performed independently with animal identification only by numbering (identified by ear notching or tail marking) as assigned prior to experimental procedure. For immunoblotting and qPCR, samples were processed and assays conducted in unblinded fashion. Note that sham and MI-operated mice present clearly observable difference to the investigator upon visualization of echocardiogram or accessing the heart during thoracotomy.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Included in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

(Also provided as Supplemental Table 1A)

Flow Cytometry Antibodies

Target antigen - Fluorochrome conjugate - Antibody source (sp) - Clone (if applicable) - Supplier Catalog# - Lot# - Dilution

Anti-mouse antibodies

B220 (CD45RA) - FITC, Pacific Blue™ - Rat IgG2a k - RA3-6B2 - BD Biosciences 553087, 558108 - 5064828, 3067597 - 1/450
PerCP-Cy5.5 552711 3267562

BST-2 (PDCA-1/CD317) - APC - Rat IgG2b k - eBio927 - Affy/eBioscience 17-3172 - 2062633 - 1/450

CD3 - PE - Armenian Hamster 145-2C11 - Affy/eBioscience 12-0031-82 - E00991-1634 - 1/600

CD3 - PE-Cy7, FITC - Armenian Hamster 145-2C11 - BD Biosciences 552774, 553062 - 54375, 65636 - 1/450

CD4 - APC, FITC - Rat IgG2a k - RM4-5 - BD Biosciences 553051, 553046 - 20510, M034512 - 1/450

CD8a - APC - Rat IgG2a k - 53-6.7 - BD Biosciences 553035 - M09126 - 1/450

CD11b - APC-Cy7 - Rat IgG2b k - M1/70 - BD Biosciences 557657 - B281906 - 1/450

CD11c - PE-Cy7, FITC - Armenian Hamster - HL3 - BD Biosciences 558079, 557400 - B283503, 28864 - 1/600, 1/450

CD19 - PE, FITC - Rat IgG2a k - 1D3 - BD Biosciences 557399, 561740 - 49622, D614061 - 1/600

CD45 - AlexaFluor488, Pac Blue Rat - IgG2b k - 30-F11 - BioLegend 103122, 103126 - 70643, B272423 - 1/600

CD45.1 - APC - Mouse IgG2a k - A20 - BD Biosciences 558701 - 57792 - 1/400

CD45.2 - PE-Cy7 - Mouse IgG2a k - 104 - BioLegend 108829 - B128066 - 1/450

CD80 - APC - Armenian Hamster 16-10A1 - BD Biosciences 560016 - 1/450

F4/80 - PE - Rat IgG2a k - BM8 - Affy/eBioscience 12-4801-82 - E01705-1636 1/600

F4/80 - Alexafluor 647, 488 Rat IgG2a k - T45-2342 - BD Biosciences 565854, 567201 - 7178647 - 1/450

IgG2a k isotype control - eFluorR 450 - Rat IgG2a k - eBR2a - Affy/eBioscience 48-4321-82 - 1/600

IgG2b k isotype control - APC, PerCP-eFluorR 710 - Rat IgG2b k - eB149 - Affy/eBioscience 17-4031, 46-4031 - E07254-1633, - 1/450
E10973-1632

IL-17A - eFluorR 450 - Rat IgG2b k - eBio1787 - Affy/eBioscience 48-7177 - E15799-107 - 1/500

Ly6C - Brilliant Violet 421 - Rat IgG2c k - HK1.4 - BioLegend 128032 - B232011 - 1/600

Ly6G - PE, FITC - Rat IgG2a k - 1A8 - BD Biosciences 551461, 551460 - 3337642 - 1/600

MHC Class II (H-2d) - FITC - Rat IgG2a k - 34-2-12 - BD Biosciences 553579 - M071786 - 1/450

NK1.1 - PE, FITC - Mouse IgG2a k - PK136 - BD Biosciences 557391, 553164 - 3166567, 67735 - 1/600

SiglecH - PerCP-eFluor710 - Rat IgG2b k - eBio440c - Affy/eBioscience 46-0333 - 2172704 - 1/450
 TRAIL (CD253/Apo 2L) PE - Rat IgG2a k - N2B2 - BioLegend 109305 - B218628 - 1/600
 Anti-human antibodies
 B220 (CD45RA) - FITC - Mouse IgG2b k - H100 - BD Biosciences 555488 - 0016333 - 1/250
 CD11b - PE-Cy7 - Rat DA/HA IgG2b k - M1/70 - BD Biosciences 552850 - 9311513 - 1/400
 CD11c - Brilliant Violet711 - Mouse IgG1 k - B-ly6 - BD Biosciences 563130 - 9169751 - 1/250
 CD14 - PE - Mouse IgG2b k - MfP9 - BD Biosciences 562691 - 0086812 - 1/600
 CD16 - Brilliant Violet421 - Mouse CDF1 IgG1 k - 3G8 - BD Biosciences 562874 - 0251273 - 1/450
 CD123 - PE - Mouse IgG2a k - 7G3 - BD Biosciences 554529 - 9183660 - 1/600
 CD303 (BDCA-2) - Brilliant Violet™ 421 - Mouse IgG2b k - V24-785 - BD Biosciences 566427 - 9296610 - 1/450
 HLA-DR - APC-H7 - Mouse IgG2a k - G46-6 - BD Biosciences 561358 - 0023290 - 1/250

(Also provided as Supplemental Table 1B)

Immunofluorescence Antibodies

Target antigen - Antibody source (sp) - Clone (if applicable) - Supplier, Catalog# - Lot# - Dilution

Primary antibodies

CD3zeta (anti-TcR) - Mouse - ThermoFisher (Zymed) 13-7700 - 71239783 - 1/50

Troponin T (cardiac) - Mouse - 13--11 - Abcam ab33589 - 1/200

BST-2 (PDCA/CD317) - Rat IgG2b k - eBio927 - Affy/eBioscience 17-3172 - E027956 - 1/40

DR5 (TRAIL-R2) - Rabbit - Novus Biologicals NB60-1091 - GA231 - 1/40

PCNA - Mouse - Millipore MAB424 - 0605029436 - 1/50

TRAIL (CD253/Apo 2L) - Mouse IgG1 - 75411.11 - Abcam ab10516 - GR3286135-1 - 1/40

IL-17A - Rat - TC11-18H10.1 - Abcam ab48494 - 1/40

Fluorochrome conjugate - Antibody source (sp) - Clone (if applicable) - Supplier Catalog# - Lot# Working dilution

Secondary antibodies

AlexaFluor® 488 anti-mouse IgG Fab2 - Cell Signaling Technology 4408S - R11/2015-11 - 1/750

AlexaFluor® 488 anti-rabbit IgG Fab2 - Cell Signaling Technology 4412S - R08/2014-11 - 1/750

AlexaFluor® 488 goat anti-rat IgG - ThermoFisher A-11006 - 45967A - 1/500

AlexaFluor® 555 goat anti-mouse IgG - ThermoFisher A-32727 - 1 in 750

AlexaFluor® 555 goat anti-rat IgG - ThermoFisher A-48263 - 1 in 750

AlexaFluor® 594 goat anti-mouse IgG - ThermoFisher A-11005 - 1713721 - 1/500

AlexaFluor® 594 goat anti-rat IgG - ThermoFisher A-11007 - 49440A - 1/500

AlexaFluor® 647 chicken anti-rabbit IgG - ThermoFisher A-21469 - 1371035 - 1/500

Non Immune dyes

Click-iT EDU® TUNEL 594 - ThermoFisher C10246 Usage as recommended

Isolectin GS-IB4 488 - ThermoFisher I21411 Usage as recommended

(Also provided as Supplemental Table 1C)

Immunoblot antibodies

Target antigen - Antibody source (sp) - Clone (if applicable) - Supplier Catalog# - Lot# - Dilution

Actin - Rabbit (Rb) - EPR16769 - Abcam ab179467 - 1/1,000

Annexin A1 - Rabbit - D16A10 - Cell Signaling/NEB 8691 - R01/2015-1 - 1/1,000

Caspase 8 - Rabbit - D35G2 - Cell Signaling/NEB 4790 - R10/2015-2 - 1/750

clAP1 - Rat - IE1-1-10 - Enzo ALX-803-335-C100 - 09031909 - 1/1,000

clAP2 (anti-human) - Rabbit - 58C7 - Cell Signaling/NEB 3130 - R12/2023-6 - 1/600

Caspase 3 - Rabbit - E87 - Abcam ab32351 - GR219726-15 - 1/1,000

cleaved Caspase 8 - Rabbit - D5B2 - Cell Signaling/NEB 8592 - R10/2015-2 - 1/750

DR5 (TRAIL-R2) - Rabbit - Novus (Biotechnie) NB20-1091 - GA231 - 1/750

GAPDH - Mouse - GA1R - Novus MA5-15738 - 1/5,000

HMGb1 - Rabbit - Millipore Sigma 07-584 - 2295660 - 1/750

IAP (pan-specific) - Rabbit - MBL CY-P104 - 14015 - 1/800

IL-1alpha - Rabbit - Abcam ab109555 - GR45718-27 - 1/750

IRAK4 - Mouse - 2H9 - Abcam ab119942 - GR313434-13 - 1/1,000

IRF1 - Mouse - 13H3A44 - BioLegend 657602 - B271557 - 1/800

IRF3 - Rabbit - Novus NBP-1-02971 - 9027 - 1/1,000

IRF7 - Rabbit - Cell Signaling/NEB 4920 - R04/2013-2 - 1/650

IRF8 - Rabbit - D20D8 - Cell Signaling/NEB 5628 - R11/2014-1 - 1/750

MyD88 - Rabbit - D80F5 - Cell Signaling/NEB 4283 - R11/2014-2 - 1/750

p50 NfκB1 - Rabbit - Cell Signaling/NEB 3035 - R10/2011-3 - 1/750

p65 RelA - Rabbit - D14E12 - Cell Signaling/NEB 8242 - 1/750

RIPK1 - Mouse - BD Biosciences 610458 - 2300502 - 1/1,000

STAT1 - Rabbit - Cell Signaling/NEB 9172 - 1/800

STAT1 - Mouse - 15H3 - ThermoFisher MA1-037 - XB345088 - 1/1000

TGfb1 - Rabbit - Abcam ab25121 - 928513 - 1/1,000

TLR9 - Mouse - 26C593 - Santa Cruz sc-52966 - H1412 - 1/750

TNFalpha - Rabbit - Cell Signaling/NEB 3707 - R12/2015-4 - 1/500

TNFR1 p55 - Rabbit - Enzo ADI-CSA-815 - 03051232 - 1/750

TRAF3 - Mouse - G-6 - Santa Cruz sc-6933 - E0165 - 1/800

TRAF3 - Rabbit - Millipore Sigma ABE585 - VP1310256 - 1/800

TRAF6 - Rabbit - D21G3 - Cell Signaling/NEB 8028 - R06/2018-2 - 1/650

TRAF6 - Rabbit - Enzo ADI-AAP-426-E - 01281317 - 1/750

TRAIL - Rabbit - C92B9 - Cell Signaling/NEB 3219 - R02/2019-2 - 1/650

TRAIL - Mouse - 75411.11 - Abcam ab10516 - GR3286135-1 - 1/600

Troponin T (cardiac) - Mouse - 1C11 - ThermoFisher MA1-16687 - X13670491 - 1/1,500

polyUbiquitin (K48) - Rabbit - EP8589 Abcam ab140601 - GR103935-11 - 1/750

polyUbiquitin (K63) - Mouse - HWA4C4 - Enzo PW-0600 - 03051236 - 1/1,000

total Ubiquitin - Rabbit - ThermoFisher 1859660 - OH190970 - 1/1,000
 Xiap - Mouse - 117320 - BioTechne (R&D) MAB822 - DYJ011911A - 1/1,000
 Vinculin - Mouse - VIN-11-5 - Millipore Sigma V4505 - 016M4857V - 1/1,500

ELISA

Target antigen - Supplier, Catalog# - Lot#
 anti-human cIAP1 - Millipore Sigma RAB1369 - 1217F2372
 anti-human cIAP2 - Millipore Sigma RAB0027 - 0512I370, 1124H370
 anti-mouse IL-10 - R&D Systems (Biotechne) DY417 (duoset) - 1375421
 anti-mouse IL-23 - R&D Systems DY1887 (duoset) - 325117

(Also provided as Supplemental Table 1D)

RT qPCR Primers

Gene Name	Protein Name	Forward Primer	Reverse Primer
Actnb	b-actin	5' - CGTACACCAGGGTGCATGG - 3'	5' - TGTAGAAGGTGTGGTCCAGAT - 3'
Ccl2	Ccl2	5' - GCTGGAGCATTACCGTGTG - 3'	5' - CTGCTGCTGGTGATCCTCTTGT - 3'
Ccr2	Ccr2	5' - GAGGGCATTGGATTCACCACA - 3'	5' - TGCCGTGGATGAACGTGAGGTA - 3'
Ctgf	Ctgf	5' - CAAAGCAGCTGCAAATACCA - 3'	5' - GGCCAAATGTGCTCTCCAGT - 3'
Cxcl1	Cxcl1	5' - AGCCACCCGCTCGCTTCTCT - 3'	5' - ACAGCGCAGCTCATTGGACGA - 3'
Hprt	Hprt	5' - CAAGCTTCGTGGTGAAAAGGA - 3'	5' - TGAAGTACTATTATAGTCAAGGGGATATC - 3'
Il1a	IL-1a	5' - CGAAGACTACAGTTCTGCCATT - 3'	5' - GACGTTCAAGGTTCTCAGAG - 3'
Il1b	IL-1b	5' - GAAATGCCACCTTTTGACAGTG - 3'	5' - TGGATGCTCTCATCAGGACAC - 3'
Il1rl1 (ST2)	St2/IL-33R	5' - ACCAACTACATCGTGAGCGC - 3'	5' - TTGCCAAAGCAAGCTGAACA - 3'
Il6	IL-6	5' - CTGCAAGAGACTCCATCCAG - 3'	5' - AGTGGTATAGACAGTCTGTTGG - 3'
Il33	IL-33	5' - AGACCAGGTGCTACTAGGCT - 3'	5' - ACGTCACCCCTTTGAAGTCT - 3'
Myh6	Myosin heavy chain, alpha subunit	5' - TGCCTACGGAAACATGAAGTT - 3'	5' - CGATGGAATAGTACACTTGTCTGT - 3'
Myh7	Myosin heavy chain, beta subunit	5' - ACTGTCAACACTAAGAGGGTC - 3'	5' - TTGGATATTTGATCTTCCAGGG - 3'
Nppb	Brain natriuretic peptide	5' - GAGGTCACTCCTTCTCTGG - 3'	5' - GCCATTTCTCCGACTTTTCTC - 3'
Tgfb1	Tgfb1	5' - ATCCTGTCCAACTAAGGCTCG - 3'	5' - ACCTCTTAGCATAGTAGTCCGC - 3'
Tnfa	Tnfa	5' - CCCTCACACTCAGATCAT CT - 3'	5' - GCTACGACGTGGGCTACAG - 3'

Validation

Routinely used antibodies, as ascertained in literature or frequently in the laboratory, were employed according to manufacturer's specifications or published protocols. Novel or less frequently used antibodies, notably antibodies against BST-2, Siglec H and TRAIL, for flow cytometry analyses were validated by titration, FMO and use of isotype control in pilot experiments. For immunofluorescence, all primary antibodies used were assessed for specificity by staining a replicate tissue section with secondary antibody in absence of primary reagents. For immunoblotting, where possible, multiple antibodies raised against epitopes of the target protein were used to verify antibody specificity(ies).

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

Murine bone marrow-derived plasmacytoid dendritic cells were generated using standard protocols (Onai, N et al, J Exp Med, 2006); briefly, whole bone marrow cells were flushed from femurs in aseptic conditions and plated in 12-well culture dishes with RPMI-1640 + 5% fetal bovine serum and supplemented with 50ng/ml Flt3 ligand every three days until the prominent visual majority of viable, adherent cells (after washing) exhibited plasmacytoid morphology. For the last three days cells were additionally treated with 5uM poly I:C to enhance cell maturation (Chen, Y-L et al, J Exp Med, 2013). Our experiments typically consisted of a 7 day differentiation period (including the maturation cycle). Cells were subsequently treated for 48 hours as indicated in methods and lysates were collected for immunoblot analyses.

Authentication

Derived primary cells were not authenticated; morphology and response to inflammatory stimuli with expression of defined signal transduction intermediates was evaluated in replicate experiments.

Mycoplasma contamination

Mycoplasma contamination was not assessed

Commonly misidentified lines (See [ICLAC](#) register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

C57Bl/6-background B6.45.1 (B6.SJL-Ptprca Pepcb/BoyJ) mice purchased from Jackson Laboratories (Bar Harbour, Me, USA); C57Bl/6 (CD45.2), cIAP1-/-, cIAP2-/-, Tlr4-/-, Nod1-/- and TNFR1-/- mice were bred and housed in the University of Ottawa Heart Institute animal facility. Due to challenges raising suitable numbers of knockout animals for specific studies and because mice were bred and housed for multiple generations prior to experimental use in identical facility environment (air flow, chow and water), heterozygous breeding-derived littermates (WT and KO) were not used in these studies. All study animals were 12-16 week old when used for experimental procedures.

Wild animals	No wild animals were used
Reporting on sex	Sex was considered as part of the studies presented, recognizing that male and female mice present differences in response to myocardial infarction. Male mice were generally used for all experimental work but female C57Bl/6 and cIAP2 ^{-/-} mice were used in studies as specifically indicated. The overall study hypothesis was tested using both male and female mice to verify if knockout of cIAP2 conferred benefit to heart function and pathological response following MI.
Field-collected samples	No samples were collected in the field
Ethics oversight	All animal procedures were carried out to comply with regulations and standard procedures provided by the University of Ottawa Animal Care Committee, and specifically procedures were followed as verified in Animal Use Protocols HI-1698, HI-3536, HI-2466 and HI-3727.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	<p>Murine peripheral blood: Whole blood (50-100ul) was collected by temporal vein lancet puncture into heparinized tubes and lysed with 20 volumes of cold red blood cell lysis buffer (150mM NH₄Cl, 20mM K₂HCO₃, 0.1mM EDTA). Suspensions were centrifuged at 330xg, non-lysed pellets were resuspended in PBS supplemented with 1% BSA.</p> <p>Spleens: whole mouse spleens were excised, washed in cold sterile PBS and disrupted by crushing through 40um nylon mesh strainers. Cells were centrifuged at 330xg and resuspended in 1ml of red cell lysis buffer. Non-lysed cells were re-centrifuged at 330xg and cell pellets were resuspended in PBS/1% BSA.</p> <p>Bone marrow: Murine femur bones were excised, cleaned and washed with cold ethanol and PBS, sequentially. Bones were subsequently crushed using a mortar and pestle. Isolated marrow was resuspended in cold PBS and strained through a 40um nylon mesh filter. Cell suspensions were centrifuged at 330xg and resuspended in PBS/1% BSA.</p> <p>Hearts: mouse hearts were excised and left ventricular tissue was dissected, washed in cold PBS, weighed and transferred to digestion cocktail (113mM NaCl, 0.6mM KH₂PO₄, 0.6mM Na₂HPO₄, 20mM HEPES (pH 7.5), 20mM NaHCO₃, 5mM KCl, 2mM MgCl₂, 1mM EDTA, 60U/ml DNase I, 100U/ml hyaluronidase, 450U/ml collagenase I, 250U/ml collagenase II and 125U/ml collagenase D). Digestion tubes were incubated at 37C for one hour with rapid shaking, and resulting suspensions were filtered through 40um nylon strainers by washing with PBS. Cell suspensions were centrifuged at 330xg and resuspended in PBS/1% BSA.</p>
Instrument	A Becton-Dickinson FACSAriaIII (lasers: 405nm, 488nm, 561nm, 633nm) was used for all flow cytometry and FACS data and sample collection
Software	Acquisition software: FACSDiva V8.2 (BD) Analysis software: FACSDiva V8.2 and FlowJo V10.4 (Treestar)
Cell population abundance	Cardiac monocyte and DC populations represent less than 1% of the total immune cell population at steady state or following acute inflammatory phase resolution; yield of recovered viable cells is considerably lower following FACS. Absolute yields vary dependent upon treatment. A minimum of 50,000 cells/mouse were required for use in quantitative experiments. Where FACS was used, post sort population purity was estimated to be >95% assessed by cytometry analysis of recovered sample. Samples plated for culture or protein analyses were frequently assessed for immune activation or specific phenotypic markers (i.e. for pDC, rare DC subtype) by immunoblot of isolated cell lysates.
Gating strategy	<p>Representative gating strategy for identifying cell populations is as follows; full description is located in Supplemental Figure 1</p> <p>Myeloid cell gating (spleen and peripheral blood samples) (Y axis vs X axis) SSC-A vs FSC-A ->> FSC-H vs FSC-W ->> SSC-H vs SSC-W ->> Lineage (CD3+/CD19+/Ly6G+/NK1.1+/F4/80+)-PE vs CD11b-APC-Cy7 ->> Lineage(lo), CD11b+: Ly6C-BV421 vs CD11c-PE-Cy7 ->> Ly6Chi, CD11c(lo): SSC-A vs FSC-A (Ly6Chi monocytes) ->> Ly6C(lo), CD11c(hi): myeloid DC (mDC) ->> Ly6C(lo), CD11c(lo): SSC-A vs FSC-A (Ly6C(lo) monocytes) ->> Lineage(hi), CD11b(hi) ->> SSC-A vs Ly6C ->> SSC-Ahi, Ly6C+: neutrophils</p> <p>Non-myeloid cell gating (non heart) ->> Lineage(lo), CD11b(lo): CD11c vs B220 (CD45RA)-FITC ->> CD11c(int), B220(int): Siglec H-PerCP-Cy5.5 vs BST-2 (PDCA-1)-APC ->> SiglecH(hi), BST-2(hi): plasmacytoid DC (pDC)</p>

Representative gating dotplots are provided in Extended Data Figures

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.